Incorporating Filastatin into medical plastics to minimize nosocomial fungal infections by Lipsky, Zachary William
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2016
Incorporating Filastatin into medical plastics to
minimize nosocomial fungal infections
Zachary William Lipsky
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Lipsky, Z. W. (2016). Incorporating Filastatin into medical plastics to minimize nosocomial fungal infections. Retrieved from
https://digitalcommons.wpi.edu/mqp-all/1966
1 
 
 
Incorporating Filastatin into 
medical plastics to minimize 
nosocomial fungal infections 
 
A Major Qualifying Project 
Submitted to the faculty 
Of 
WORCESTER POLYTECHNIC INSTITUTE 
 
In partial fulfillment of the requirements for the 
Degree of Bachelor of Engineering  
in Biomedical Engineering1 
And 
Degree of Bachelor of Science 
In Biochemistry2 
By 
__________________ 
 
Zachary Lipsky1  
__________________ 
 
Bonham Pierce2 
 
Submitted on 
 
April 28, 2016 
 
By 
________________________________ 
 
Marsha Rolle Ph.D, Project Advisor 
________________________________ 
 
Destin Heilman Ph.D, Project Advisor 
2 
 
Table of Contents 
 
Authorship .................................................................................................................................................... 5 
Acknowledgments ......................................................................................................................................... 5 
Table of Tables .............................................................................................................................................. 5 
Table of Figures ............................................................................................................................................. 5 
Abstract ......................................................................................................................................................... 7 
Chapter 1: Introduction ................................................................................................................................ 8 
Chapter 2: Literature Review ...................................................................................................................... 11 
C. Albicans ............................................................................................................................................... 11 
Urinary Catheters .................................................................................................................................... 12 
Filastatin .................................................................................................................................................. 13 
Current Treatment Methods .................................................................................................................. 15 
Prevention: Current Antifungal Materials .............................................................................................. 18 
Polymerization .................................................................................................................................... 19 
Simple Coating .................................................................................................................................... 20 
Covalently bonding to the surface through an organic tether ........................................................... 21 
Absorption .......................................................................................................................................... 22 
Entrapment ......................................................................................................................................... 22 
Conclusion ............................................................................................................................................... 23 
Chapter 3: Project strategy ......................................................................................................................... 24 
Initial and Revised Client Statement ....................................................................................................... 24 
Objectives ............................................................................................................................................... 24 
Constraints .............................................................................................................................................. 28 
Engineering Standards ............................................................................................................................ 28 
Functions ................................................................................................................................................. 31 
Project approach ..................................................................................................................................... 31 
Incorporating Filastatin ....................................................................................................................... 31 
Measuring Cell Adhesion .................................................................................................................... 32 
Longer term simulated in vivo testing ................................................................................................ 35 
3 
 
Chapter 4: Alternative Designs ................................................................................................................... 36 
Polymerization ........................................................................................................................................ 36 
Using a Functionalizing Agent ................................................................................................................. 39 
Absorption .............................................................................................................................................. 42 
Entrapment ............................................................................................................................................. 44 
Conclusion ............................................................................................................................................... 46 
Chapter 5: Design Verification .................................................................................................................... 47 
Reaffirming effectiveness with multiple replicates ................................................................................ 47 
Calculating elution rate ........................................................................................................................... 48 
Testing the versatility of the incorporation method .............................................................................. 51 
Switch to catheters ................................................................................................................................. 53 
Cost Analysis ........................................................................................................................................... 56 
Testing long-term .................................................................................................................................... 58 
Chapter 6: Discussion .................................................................................................................................. 63 
Analysis and Limitations of Experiments ................................................................................................ 65 
Impact Analysis ....................................................................................................................................... 65 
Economics ........................................................................................................................................... 65 
Environmental Impact ......................................................................................................................... 66 
Social Influence ................................................................................................................................... 66 
Political Ramifications ......................................................................................................................... 66 
Ethical Concerns .................................................................................................................................. 67 
Health and Safety Issues ..................................................................................................................... 67 
Manufacturability ............................................................................................................................... 67 
Sustainability ....................................................................................................................................... 68 
Chapter 7: Final Design and Validation ....................................................................................................... 69 
Part 1: Preliminary screening .................................................................................................................. 69 
Part 2: Physiologically accurate testing .................................................................................................. 70 
Part 3: Final design selection .................................................................................................................. 70 
Chapter 8: Conclusions and Recommendations ......................................................................................... 71 
Recommendations .................................................................................................................................. 71 
4 
 
Urine pump with artificial bladder & ureter ....................................................................................... 71 
Standardizing cell count for the overnight culture ............................................................................. 71 
Creating samples identical replicates ................................................................................................. 72 
Future work ............................................................................................................................................. 73 
References .................................................................................................................................................. 74 
Appendix A: ................................................................................................................................................ 82 
Appendix B ................................................................................................................................................. 83 
Appendix C ................................................................................................................................................. 85 
Appendix D ................................................................................................................................................. 86 
Appendix E ................................................................................................................................................. 88 
Appendix F ................................................................................................................................................. 89 
Appendix G ................................................................................................................................................. 90 
Appendix H: ................................................................................................................................................. 92 
Appendix I: .................................................................................................................................................. 97 
Appendix J: .................................................................................................................................................. 98 
Appendix K: ................................................................................................................................................. 99 
Appendix L: ............................................................................................................................................... 100 
Appendix M: .............................................................................................................................................. 101 
Appendix N: ............................................................................................................................................... 102 
Appendix O:............................................................................................................................................... 104 
Appendix P: ............................................................................................................................................... 108 
Appendix Q: .............................................................................................................................................. 110 
 
 
 
 
5 
 
Authorship 
 This report is the product of the collaboration between two students. It was written by Zachary 
Lipsky and edited by Bonham Pierce.  
Acknowledgments 
 We would like to extend our thanks to the following individuals for their continued assistance, 
guidance, and advice throughout the completion of this Major Qualifying Project: 
 
Dr. Paul Kaufman of UMass Medical School, for his support in coordinating and sponsoring our research 
Dr. Marsha Rolle of Worcester Polytechnic Institute, for her guidance, advice, and encouragement 
Dr. Destin Heilman of Worcester Polytechnic Institute, also for his guidance, advice, and encouragement  
Dr. Reeta Rao of Worcester Polytechnic Institute, for her expertise in the field 
Diego Vargas of Worcester Polytechnic Institute, for his help in developing the cell adhesion assay 
Collaborators at the University of Massachusetts: Lowell, for providing polymerized Filastatin squares 
Table of Tables 
Table 1: Primary drugs to treat C. albicans infection and targets .............................................................. 16 
Table 2: Pairwise Comparison Chart – Objectives ...................................................................................... 25 
 
Table of Figures 
Figure 1: C. albicans pathology ..................................................................................................................... 9 
Figure 2: Induction of C.albicans using Spider media (1-8 hrs.) .................................................................. 12 
Figure 3: Signaling pathways that govern hyphal morphogenesis and proposed Filastatin effect ............ 14 
Figure 4: (a) Targets of current antifungal drugs in C. albicans. (b) Mechanisms of resistance to antifungal 
drugs in C. albicans. (adapted from Cannon, et al., 2007) .......................................................................... 18 
Figure 5: Objectives Tree ............................................................................................................................ 25 
Figure 6: Filastatin 25uM in Tris buffer ....................................................................................................... 26 
Figure 7: Filastatin incorporated into silicone squares incubated in 25 uM Filastatin for 24 hrs. ............. 26 
Figure 8: Absorbance versus Filastatin concentration standard curve ....................................................... 32 
Figure 9: Basic methodology of the cell adhesion assay ............................................................................ 34 
6 
 
Figure 10: Conceptual design of Thiolene network polymer with Filastatin polymerized ......................... 36 
Figure 11: The thiol-ene reaction by which the polymeric infusion proposed was formed. This reaction is 
rapid, involving low toxicity liquid reagents and requiring no solvent, initiator, or other additives. ........ 37 
Figure 12: Filastatin shows sufficient thermal stability for blending with molten thermoplastics. Thermal 
stability was assessed in both air and N2, heating at 20°C/min from room temperature to 1000°C. Melt 
temperatures for the medical plastics of interest here do not exceed 250°C. (This graph was provided by 
UMass Lowell) ............................................................................................................................................. 38 
Figure 13: Normalized fluorescence values of cell adhesion assay using polymerization method ............ 38 
Figure 14: APTMS molecule ........................................................................................................................ 40 
Figure 15: Conceptual Design of using a functionalizing agent (APTMS) ................................................... 40 
Figure 16: Concentration of Filastatin in solution as it is bound onto silicone functionalized with APTMS
 .................................................................................................................................................................... 40 
Figure 17: Normalized absorbance values of cell adhesion assay using functionalizing agent method .... 41 
Figure 18: Conceptual Design of Absorption .............................................................................................. 42 
Figure 19: Concentration of Filastatin in solution as it is absorbed into silicone ....................................... 43 
Figure 20: Normalized absorbance values of cell adhesion assay using absorption method .................... 44 
Figure 21: Conceptual Design of Entrapment ............................................................................................. 45 
Figure 22: Normalized absorbance values of cell adhesion using entrapment method ............................ 45 
Figure 23: Crystal Violet assay on Silicone Squares .................................................................................... 48 
Figure 24: A) Absorbance of Filastatin eluted from silicone B) Absorbance of Filastatin eluted from 
silicone entrapped in polydopamine .......................................................................................................... 50 
Figure 25: Crystal Violet assay on Pellethane ............................................................................................. 52 
Figure 26: Crystal Violet assay on thermoplastic polyurethane ................................................................. 52 
Figure 27: Crystal violet assay done with both A) circular cross section (rings) and B) lateral bi-section 
(curved squares) ......................................................................................................................................... 54 
Figure 28: Crystal violet assay done on silicone catheter rings .................................................................. 55 
Figure 29: Crystal Violet assay on silicone catheter rings (22 hrs.)............................................................. 59 
Figure 30: Crystal Violet assay on silicone catheter rings (45 hrs.)............................................................. 59 
Figure 31: Uncoated at 22hrs. and 45 hrs. .................................................................................................. 60 
Figure 32: Polydopamine coated at 22hrs. and 45 hrs. .............................................................................. 60 
Figure 33: Filastatin absorbed at 22hrs. and 45 hrs. ................................................................................... 61 
Figure 34: Filastatin absorbed then Polydopamine coated at 22hrs. and 45 hrs. ...................................... 61 
Figure 35: Soluble Filastatin at 22hrs. and 45 hrs. ...................................................................................... 61 
Figure 36: No cells at 22hrs. and 45 hrs. ..................................................................................................... 62 
Figure 37:  Final design approach ............................................................................................................... 69 
Figure 38: Comparison of overnight cultures effect on cell adhesion assay .............................................. 72 
  
 
7 
 
Abstract 
Candida albicans is the fourth most common source of hospital-acquired infections in the 
United States that primarily effects urinary catheters. The estimated annual cost of treating a systemic 
C. albicans infection exceeds $200 million per year due to increasing resistance to antifungal drugs. 
Using a small molecule called Filastatin that affects cell morphology, we developed several approaches 
to integrate the molecule into silicone catheters to prevent cell adhesion. We designed several 
incorporation approaches including: 1)Polymerization 2)Functionalizing Agent 3)Absorption 
4)Entrapment. Utilizing a cell adhesion assay, we screened the various designs to classify which had the 
greatest impact on preventing cell adhesion to silicone catheters. We found through replicate testing 
that absorption had the most influence compared to the other alternatives. Once identified, we tested 
the versatility of the absorption incorporation approach on various other materials (Thermoplastic 
Polyurethane and Pellethane) and found it did not have a significant effect on cell adhesion. Lastly, we 
did a cost analysis to determine whether it would be comparable to what is currently on the market for 
antifungal catheters. 
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Chapter 1: Introduction 
Candida albicans is the fourth most common source of hospital-acquired infections in the 
United States (Wisplinghoff et al., 2004). It primarily affects immunocompromised individuals with a 
thirty to fifty percent mortality rate (Pappas et al., 2003). C. albicans can cause two types of infections: 
mucosal infections (oral and vaginal thrush) and systemic infections (candidemia) (Fidel and Sobel, 
1996). These infections usually reside from medical devices including catheters, prosthetics, grafts, and 
cardiac devices (Kojic & Darouiche, 2004). The estimated annual cost of treating a systemic C. albicans 
infection exceeds $200 million per year due to its increasing resistance to antifungal drugs (Millar et. al, 
2001). C. albicans is becoming resistant to first-line and second-line antifungal medications, namely, 
Pyrimidine, Azoles, Polyenes and Echinocandins (Morgan, 2005). For example, approximately seven 
percent of all Candida bloodstream isolates tested at the Center for Disease Control (CDC) are resistant 
to fluconazole (a type of azole) (Cleveland et al., 2012). Antifungal resistance will continue to worsen 
unless more is done to prevent further resistance and the spread of these infections.  
C. albicans cells are not pathogenic at 30°C, 5.4 pH and remain as single round budding yeast 
cells (blastospore). It is only once they are induced by several environmental conditions including pH, 
temperature, or a carbon lacking environment that they pose a threat to humans. (Fazly et. al., 2013) 
Once the C. albicans are induced, they start filamentation in which the cells form small projections called 
“germ tubes” and continue to divide at the apical tip of the tubes to form extended filaments or hyphae 
(Odds, 1988; Lo et al., 1997; Brown, 2002; Saville et al, 2003) (Figure 1). Hyphae allow the cells to adhere 
to implanted medical devices and human epithelial cells by proteins called adhesins (Kumamoto and 
Vinces, 2005). These proteins allow the cells to adhere to one another and form biofilm over the surface 
with which they come into contact. Biofilm is a polysaccharide extracellular matrix produced by the cells 
in order to shield them from external threats like antibodies and antibiotics (Chandra et al., 2001). 
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Biofilm formation is harmful because once it forms on a medical device (i.e. intravascular devices or 
catheters) they are difficult to remove and can cause diseases as described previously. These medical 
devices often have to be surgically removed (Chauhan, 2012). 
 
Figure 1: C. albicans pathology 
To combat the increasing resistance of C. albicans to typical treatment methods, scientists 
including Dr. Paul Kaufman at the University of Massachusetts conducted a high-throughput phenotypic 
screening of small molecules to identify compounds that inhibit adhesion of C. albicans to polystyrene 
plates (Fazly, 2013). Adhesion is the first step of the pathogenesis of C. albicans, and without it, the 
fungus cannot form pathogenic biofilm. From the screening of small molecules, they found a candidate 
that prevented C. albicans’ adhesion called Filastatin (Fazly, 2013). The goal for this molecule and the 
initial client statement for our project was to develop a medical grade antifungal plastic to stop the 
spread of nosocomial fungal infections from medical devices by incorporating Filastatin and preventing 
adhesion of C. albicans. 
 With this goal in mind, we developed alternative designs to incorporate the small molecule 
Filastatin into urinary catheters.  Urinary catheters are the most commonly used devices in the U.S. that 
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acquire C. albicans infections (Kojic & Darouiche, 2004). They have the greatest overall infection rate 
between 10-30%. To achieve our goal, we identified four objectives of our design:  
1. Successfully incorporate Filastatin into a medical grade plastic 
2. Decrease cell adhesion to the plastic 
3. Versatile to a number of medical plastics 
4. Cost effective 
To detect if Filastatin was integrated into the device, we used spectroscopy. Filastatin is a bright yellow 
molecule that absorbs around 400 nm. It was found that absorbance reading correlated linearly with a 
concentration curve. Therefore, segments of catheter were placed in a solution of Filastatin in Tris 
buffer and over a 2-day period, 1 ml of solution was taken out and measured and the same 1 ml of 
solution was put back to not alter the concentration from start to finish. To measure if there was a 
decrease in cell adhesion, we developed a quantitative assay using a crystal violet or Alamar blue dye to 
proportionally quantify how many cells adhered to the plastic. To check versatility, the method of 
incorporation and cell quantification assay was repeated using various plastics typically used for 
catheters. Lastly, to determine if the incorporation method would be easily manufacturable, we 
calculated how much it might cost to integrate Filastatin into catheter production based on its necessary 
concentration and price. After our preliminary testing was completed, we verified effectiveness through 
a longer assay of 2 days at a more physiologically relevant cell number (1000 cells) (Achkar and Fries, 
2010). 
 The next chapters will discuss C. albicans infections, urinary catheters, Filastatin and current 
treatment methods. We will also explore antifungal drugs as well as methods for producing antifungal 
plastics. We will explain our project’s development and the alternative designs developed and tested.  
We will conclude by presenting our results and discussing the implications of our findings. 
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Chapter 2: Literature Review 
The goal of this project was to develop strategies to incorporate Filastatin with anti-fungal 
properties into a medical material to prevent Candida albicans infections. The chapter has detailed 
background information and literature on C. albicans’ characteristics, urinary catheters, the small 
molecule Filastatin, current treatment methods and methods to prevent fungal pathogen adhesion. 
C. Albicans 
C. albicans is an opportunistic infectious agent in humans that grows both as yeast and 
filamentous cells (Sherris, 1984). C. albicans is largely dependent on its cell wall. Its unique structure 
provides protection against host immune response and allows it to adhere to surfaces (Ruiz-Herrera 
2006). A primary difference between C. albicans and other fungi is the presence of antigens in its cell 
wall that control homeostatic balances to favor C. albicans over other normally present microbes (Ruiz-
Herrera, 2006).  
C. albicans are non-pathogenic under normal conditions (30°C, 5.4 pH) and presents itself as 
blastospores, or budding yeast cells (Wisplinghoff et al., 2004). When C. albicans are induced by 
environmental conditions, including changes in pH, temperature, or a carbon lacking environment (Fazly 
et. al., 2013), blastospores begin changing morphologically to a pathogenic microbe (Figure 2). Initially 
(zero to two hours after induction), the C. albicans cell starts to form germ-tubes as they make contact 
with a surface (Figure 2) (Chandra, Jyotsna, et al., 2001). At three to four hours, distinct microcolonies 
appear on the surface (Figure 3). After eight hours (Figure 4), C. albicans communities appear as thick 
tracks of fungal growth, due to cell growth and aggregation along areas of surface irregularities. This is 
the first phase of biofilm formation.  
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Figure 2: Induction of C.albicans using Spider media (1-8 hrs.) 
C. albicans biofilm formation has three distinct developmental phases: early (eight to eleven 
hours), intermediate (twelve to thirty hours) and maturation (thirty-eight to seventy-two hours) 
(Chandra, Jyotsna, et al., 2001). The intermediate developmental phase is characterized by the 
emergence of extracellular material which appears as a haze-like film covering the fungal microcolonies. 
This film is composed mainly of cell-wall-like polysaccharides. At maturation, the amount of extracellular 
material increases with incubation time until the communities of cells completely encase the material.   
Urinary Catheters 
 Urinary catheters are the most commonly used devices in the U.S. that acquire C. albicans 
infections (Kojic & Darouiche, 2004). They have the greatest overall infection rate between 10-30%. A 
urinary catheter is a tube placed in the body to drain and collect urine from the bladder. Catheters come 
in various sizes, plastics (latex, thermoplastic polyurethane, pellethane, and silicone), and types 
(Lawrence and Turner, 2005). There are two main types of catheters including indwelling and 
intermittent.  
An indwelling urinary catheter is one that is left in the bladder for either a short (<14 days) or 
long period of time (>14 days) (Pickard et al., 2012). An indwelling catheter collects urine by attaching to 
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a drainage bag. A newer type of catheter has a valve that can be opened to allow urine to flow out. An 
indwelling catheter may be inserted into the bladder in two ways. Most often, the catheter is inserted 
through the urethra. This is the tube that carries urine from the bladder to the outside of the body. 
Sometimes, the provider will insert a catheter into your bladder through a small hole in the abdomen. 
This is done at a hospital or provider's office. An indwelling catheter has a small balloon inflated on the 
end of it. This helps the catheter maintain its position in the body. When the catheter needs to be 
removed, the balloon is deflated. 
An intermittent urinary catheter is used when the individual only needs the catheter on multiple 
short instances or the person does not want to wear a bag (Wilde et al., 2011). The individual will insert 
the catheter to drain the bladder and then remove it him/herself.  
Filastatin 
Filastatin was discovered through high-throughput phenotypic screening of small molecules that 
hinder adhesion of C. albicans to polystyrene, cultured human epithelial cells, and silicone elastomers 
(Fazly, 2013). Screening was conducted by co-incubating molecules with cells grown in Spider media (a 
carbon-lacking media that induces hyphal formation; See Appendix A) and quantifying how many cells 
adhered to the surface (whether polystyrene or silicone elastomers). What they found was that 
Filastatin significantly decreased the amount of cells adhering to the various surfaces from 50-75% over 
the course of a sixteen hrs. incubation period. In addition, assays comparing the effect of co-incubating 
cells with Filastatin, after 8 hours of cells incubating alone, showed that Filastatin also has an effect on 
cells already bound to a surface. These tests showed that Filastatin affects hyphal formation, which in 
turn, affected biofilm formation (Fazly, 2013).  
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Filastatin diminishes yeast-to-hyphal transformation and therefore reduces fungal pathogenesis. 
The exact mechanism for the interaction between Filastatin and C. albicans is unknown. It is 
hypothesized that it is caused by disrupting multiple signaling pathways (Figure 3). For example, hyphal 
induction by Spider media requires activating the cAMP-PKA pathway (Lu, Yang et al, 2011). Cells 
constantly overexpressing the G protein-coupled receptor Gpr1 became hyperfilamentous in Spider 
media by PKA stimulation, and, as previously stated, Filastatin blocks hyphal morphogenesis in this 
media (Midkiff et al., 2011). PKA pathway stimulation also drives transcription factor Efg1 
phosphorylation, activating Efg1 to increase expression of genes required for hyphal morphogenesis. 
This was confirmed with an experiment that involved hyperactive Ras1 signaling protein mutant, 
another upstream signal that governs hyphal development (Feng et al., 1999). When Filastatin was 
introduced to the Spider media with the modified cells, the effect was comparable to that of WT cells. 
 
Figure 3: Signaling pathways that govern hyphal morphogenesis and proposed Filastatin effect 
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 Other experiments suggested that Filastatin affected more than one signaling pathway. For 
example, the modified sugar GlcNac also stimulates hyphal morphogenesis but does so independently of 
the cAMP-PKA pathway; instead, it activates the transcription factor Cph1 (Midkiff and White, 2013). On 
testing morphogenesis driven by GlcNac-containing media or constitutive overexpression of Cph1, 
Fazly’s lab found that Filastatin also inhibited hyphal formation in these cases. This data indicated that 
Filastatin may affect multiple signaling pathways or could act by destroying the ability of the cell to form 
elongated structures, regardless of the inducing signal. 
 Filastatin’s effects on C. albicans’ morphogenesis has been clearly documented but not 
understood to the extent that it can be used to treat patients. C. albicans infections have been identified 
as a public health issue (Pfaller 2007), but it could take years for Filastatin to be used therapeutically. 
There are various drugs as well as antifungal treatments used to prevent infection, but these are 
becoming ineffective quickly (Pfaller 2007).  
Current Treatment Methods 
Currently, there are four types of therapeutic antifungal agents used to treat C. albicans: 
pyrimidine, azoles, polyenes and echinocandins, as shown in Figure 6 (Cannon, et al., 2007). These drugs 
create an environmental stress for C. albicans in several ways including changes in osmolality, ionic 
stress and oxidative stress (Table 1) (Cannon, et al., 2007).  
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Table 1: Primary drugs to treat C. albicans infection and targets 
Drug Target Effect Resistance 
Pyrimidine FC pathway Inhibits RNA synthesis 
and DNA replication 
Cannot convert from 5-FU to FUMP 
(Fur1p mutation) 
Polyenes Cell membrane lipid 
Bilayer (binds to 
ergosterol) 
Forms pores in the 
plasma membrane 
Lower concentration of ergosterol 
in membrane (Erg3p mutation) 
Azoles Sterol biosynthesis Accumulation of toxic 
sterol intermediates 
(fungistatic) 
Lower concentration of ergostreol 
in membrane (Erg3p 
mutation)/MFS or ABC pumps 
eject azole 
Echinocandins D-beta-glucan 
biosynthesis 
Disruption of cell wall 
biosynthesis 
Mutation in D-beta-glucan 
biosynthesis (Gsc1p)  
 
One type of pyrimidine is called fluorinated pyrimidine. The fluorinated pyrimidine (5-cytosine 
(5-FC)) acts as a suicide inhibitor by interacting with the metabolic pathway of the cell to cause cell 
death (Figure 4a). This drug interacts with  5-fluorouracil (5-FU) and uracil phosphoribosyl transferase 
(FUR1) to generate the toxic intermediate fluorouridine monophosphate (FUMP). FUMP is incorporated 
into the RNA after a double phosphorylation to create fluorouridine triphosphate (FUTP), inactivating 
the RNA template function and therefore inhibiting RNA synthesis. FUMP is also converted by 
ribonucleotide reductase (RR) and double phosphorylated to fluorodeoxyuridine triphosphate (F-dUTP), 
which inhibits DNA replication (Cannon, et al., 2007). 
 Another agent, polyenes, are heterocyclic amphipathic molecules that insert into lipid bilayers, 
bind to sterols, and aggregate in annuli to form pores (Figure 4a). The pores disrupt plasma membrane 
integrity and permit the efflux of cations, such as K+, which are biocidal for C. albicans (Cannon, et al., 
2007). 
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 The azole antifungals disrupt sterol biosynthesis process (Figure 4a). Sterol is responsible for 
controlling membrane fluidity and permeability (Piironen et. al, 2000).  Azoles start by inhibiting the 
cytochrome P450 14a-lanosterol demethylase, encoded by the ERG11 gene, which is part of the 
ergosterol biosynthetic pathway. Inhibition of Erg11p depletes the membrane ergosterol content and 
results in the accumulation of toxic sterol pathway intermediates which inhibit growth (Akins, 2005; 
Sanglard & Bille, 2002). Azoles are therefore fungistatic for C. albicans.  
The most recently developed class of antifungals is the echinocandins. These drugs are 
supposed to disrupt cell wall biosynthesis by inhibiting (1,3)-D-beta-glucan synthase (β-glucan), and 
causing a fungicidal response (Figure 4a).  
Although there are various methods to treat a C. albicans infection, there are issues with each of 
the agents (Figure 4b). A large proportion of C. albicans isolates are resistant to pyrimidine, 5-FC, due to 
a mutation in the enzyme uracil phosphoribosyl transferase (Fur1p) (Gabriel et al, 2014). This enzyme 
converts 5-fluorouracil (5-FU) to fluorouridine monophosphate (FUMP). 
Polyene resistance is caused by a plasma membrane ergosterol reduction, to which polyene 
binds. This can be caused by a mutation in ERG3, which lowers the ergosterol concentration in the 
membrane (Figure 4b). The ergosterol concentration is lowered by the accumulation of toxic ergosterol 
precursors, such as 14a-methylfecosterol and Erg11p. (Akins, 2005; Sanglard & Bille, 2002) 
An ERG3 mutation can cause resistance to azoles as well (Figure 4b). Azoles bind similarly to 
polyenes in terms of ergosterol in the plasma membrane. In addition, high azole resistance also relates 
to overexpressing the MFS pump in the plasma membrane, or the ATP binding cassette (ABC) pumps 
(Perea et al., 2001). These proteins have been found to pump azoles back outside the cell (Lamping et 
al., 2007).   
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Lastly, echinocandin-resistant C. albicans isolates have point mutations in (1,3)-b-glucan 
synthase subunit Gsc1p, which prevent echinocandins, like caspofungin, from binding to the cell wall 
(Baixench et al., 2007) (Figure 4b). 
 
Figure 4: (a) Targets of current antifungal drugs in C. albicans. (b) Mechanisms of resistance to 
antifungal drugs in C. albicans. (adapted from Cannon, et al., 2007) 
Prevention: Current Antifungal Materials 
Even with these various methods for treating C. albicans infections, the growing resistance to 
antifungal drugs (Millar et. al, 2001) highlights a need for preventative measures. Materials and 
compounds capable of inhibiting C. albicans adhesion onto medical materials have been identified as 
the best preventative measure (Palza, 2015) (Zhou, et al., 2010) (Onaizi, 2011). These material or 
compounds can have several incorporation strategies to transfer their antifungal properties to the 
medical material. We chose to focus on five incorporation methods: polymerization, simple coating, 
absorption, attachment via a functionalizing agent and entrapment by using a layering coating method. 
These methods helped in determining approaches for Filastatin incorporation.  
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Polymerization 
 Polymerizing into the monomers of a polymer is one method used to prevent C. albicans from 
adhering to medical surfaces. This can either be done by incorporating another polymer into the 
backbone of the primary polymer (Hook et al., 2012) or by curing a drug into pores that form due to 
phase separation (Langer, 2000).   
One example of polymerizing a copolymer into a medical material is the incorporation of ester 
and cyclic hydrocarbon moieties into silicone. Through a high-throughput screening of hundreds of 
material combinations, silicone polymerized with these molecules reduced adhesion of three pathogenic 
bacteria (P. aeruginosa, S. aureus, and E. coli) by 96% (Hook et al., 2012). These combinations were 
achieved through photopolymerization by a free radical mechanism.  These results were shown in vivo 
with a mouse model that exhibited a 2-fold decrease in bacterial numbers compared to silicone by itself. 
While these methods were shown to be effective with bacteria strains, similar results have yet to been 
seen with C. albicans. 
One study involving curing a drug into pores used metal nanoparticles, including copper and 
silver, incorporated into polypropylene polymer matrices (Palza, 2015). Metals can be extremely toxic to 
bacteria and yeast at exceptionally low concentrations (3-5% of the total composition of the polymer) 
(Palza, 2015). The biocide behavior is triggered by the metal oxidation potentials. The oxidative stress 
causes damage to cellular proteins, lipids and DNA. Impregnation of metal ions is carried out by 
embedding them in a highly nonpolar polymer matrix (polypropylene) (Delgado et al., 2011). The 
composite is prepared using a Brabender plastic order at 190*C, 110 revolutions per min for 10 mins, 
under a nitrogen atmosphere to avoid oxidative degradation processes. The composite is then press 
molded at 190*C at 50 bar for 5 min and cooled under pressure by flushing the press with cold water.  
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 Although metals are used currently in the urinary catheter industry (i.e. BARD medical© silver-
hydrogel catheter), its effectiveness in vivo has been minimal. In a recent paper, there was a comparison 
that involved the BARD silver hydrogel catheter, and a standard latex catheter control (Pickard et al., 
2012). In this prospective randomized clinical study, 4,241 participants were recruited from 24 sites over 
a 40-month period (2097 silver hydrogel catheter and 2144 control). Participants were individuals 
requiring temporary urethral catheterization for a period of between 1 and 14 days as part of their care, 
predominantly as a result of elective surgery. The primary outcome for clinical effectiveness was the 
incidence of UTI at any time up to 6 weeks post randomization. This was defined as any symptom 
reported during catheterization, up to 3 days or 1 or 2 weeks post catheter removal or 6 weeks post 
randomization combined with a prescription of antibiotics, at any of these times, for presumed 
symptomatic UTI.  The median duration of catheterization was 2 days and it was found that 12.5% in the 
silver alloy group and 12.6% in the control group experienced at least one symptomatic UTI in the 6 
weeks after randomization. This was not statistically significantly from one another (P=0.92).  
Simple Coating 
 Anti-microbial coatings are another way to prevent C. albicans from adhering to surfaces. 
Parylene is one of those coatings; it is used to coat many different surfaces including metal, glass, paper, 
resin, plastic, and ceramic by chemical vapor deposition and polymerization of pare-xylene (Demirel, 
2008). Parylene is thought to cut the bond between silanol groups (Si-OH), like those between the 
silicone on the surface and hydrogen atoms of proteins on the C. albicans’ surface (Zhou, et al., 2010).  
C. albicans adhesion to silicone elastomer surfaces coated with Parylene is less than uncoated samples, 
on the magnitude of 4.5x fewer cells (2.18 x 107 uncoated vs. 0.48 x 107 coated) (Zhou, et al., 2010).  
 Although effective in limiting C. albicans’ adhesion, there are some issues associated with this 
coating technique. One includes the moisture barrier performance. Parylene moisture barriers are 
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susceptible to failure after prolonged exposure at higher temperatures. Under such conditions, 
resistance to corrosion can decline due to contaminants or particles trapped inside the coating-film (Li, 
et al., 2008). Parylene’s biggest flaw is adhesion to the surface being coated. Coating can only be done 
on devices that will fit in the deposition system's coating chamber (Li, et al., 2008). Furthermore, while 
Parylene coatings are typically thin, they also deposit relatively slowly (Tooker 2007).   
Covalently bonding to the surface through an organic tether 
 Another way to create an antifungal surface is to bind a drug to the surface using an organic 
tether. Some substances, like antimicrobial peptides (AMPs), are not metabolized by the cell and instead 
require contact between cell surface and peptide through electrostatic interaction that results in a 
modification of the cell wall or membrane (Onaizi 2011). Depending on the chemically inactive groups 
on the anti-microbial peptide, it can be covalently bonded to any surface (thiol, aldehyde, epoxide, and 
amine) (Onaizi 2011). In covalent coupling, AMPs are able to form a stable antimicrobial coating on the 
surface that rejects degradation. The length of the tether can be varied from one to several carbon 
atoms, depending on the significance of space length effect on AMP activity. In addition, the orientation 
of bound AMPs can be controlled through the utilization of directed immobilization coupling reactions 
(Jonkheijm, P. et. al, 2008). 
 There are two main disadvantages to using organic tethers to bind the substance of interest to 
the surface. The first is that the substance or the flexible organic tether could be cleaved (Onaizi, 2011). 
Cleavage could occur when the surface is used in vivo, where it is susceptible to various enzymes. 
Second, most studies using tethering have shown lessened antimicrobial activity when compared to the 
substance in solution (Bagheri, 2009). While polyethylene and polypropylene have been shown to 
effectively bind with AMPs and inhibit C. albicans adhesion, these methods have not passed clinical trials 
(Nova-Ortiz 2010). 
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Absorption 
 Another method of antifungal treatment is the absorption of drugs. One study used fluconazole 
absorbed polyurethane (Donelli, 2009). The hope was to release the antifungal drug over time, inhibiting 
fungal biofilm formation on medical devices. By releasing the drug over time, the local drug 
concentration at the surface remains high enough to inhibit pathogenesis for a longer time.  Fluconazole 
was adsorbed in higher amounts by the most hydrophilic polymers and its release was influenced by the 
degree of polymer swelling in water. Drug release was noticeable through UV spectroscopy at 215 
nanometers up to nine days after incubation with C. albicans. This method inhibited C. albicans growth 
and biofilm formation (undetectable cell count) on polymeric surfaces for up to eight days.  
There are a few issue associated with this method.  One is that the polymer uses fluconazole as 
the antifungal agent. As discussed in the Current Treatment Section, fluconazole is a type of azole which, 
among other antifungal agents, has increased resistance by C. albicans. In addition, this treatment 
method elutes fluconazole for a nine-day period with no detectable biofilm formation for only eight 
days. Indwelling long-term catheters can be implanted for up to month (Saint and Lipsky, 1999), so this 
coating method would not work for these types of catheters. 
Entrapment 
A study involving entrapment was silver ions in a polydopamine film. As stated previously, 
metals can be extremely toxic to bacteria and yeast at exceptionally low concentrations (3-5% of the 
total composition of the polymer) (Palza, 2015). Polydopamine is a self-polymerizing molecule that 
forms a thin adherent film on virtually any surface under mild alkaline aqueous conditions and in the 
presence of oxygen. Moreover, exposed reactive groups of the polydopamine coatings enable further 
functionalization of the coatings through covalent grafting of polymers and allow reduction of metal 
ions to be released (Lee, 2007). Sustained silver release was observed for a little over 7 days from silver-
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coated substrates, and the release kinetics could be modulated via additional polydopamine overlayers. 
In vitro functional assays employing gram negative and positive strains demonstrated dual fouling 
resistance and antibacterial properties of the coatings due to the antibacterial effect of silver. As stated 
previously, silver ions in vivo have not shown effective results. 
Conclusion 
While there are different ways to incorporate drugs, metals, and other polymers into/onto 
medical devices, none have been shown to be both effective and versatile in vivo for a long period of 
time (up to a month). Additionally, these methods are expensive and resistance to them is increasing. 
With the new discovery of the small molecule Filastatin, our team’s design goal will be to use some of 
these incorporation methods to create the optimal fusion that is cost effective, versatile, and shows a 
sustained effect on C. albicans.  
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Chapter 3: Project strategy 
 This chapter describes the steps taken to prioritize the various objectives and constraints for the 
design. The project approach section outlines the steps necessary to design and test alternatives for 
Filastatin incorporation into medical plastic for urinary catheters. 
Initial and Revised Client Statement 
Our client, Professor Kaufman at the University of Massachusetts Medical School, initially 
challenged us with the task of incorporating Filastatin in a medical plastic to inhibit filamentation. 
Without the ability to filament and form hyphae, C. albicans would not adhere to a surface and then 
form biofilm on medical devices. By doing this we would create a medical plastic capable of preventing 
C. albicans infections from occurring. It was then our task to research alternative techniques that could 
be used to incorporate Filastatin. As we developed an understanding of various techniques, as well as 
what is currently being produced on the market, we began compiling a list of objectives and constraints. 
Utilizing our objectives and constraints, we developed functions and specifications for designs. We 
found that urinary catheters are the most commonly used devices in the U.S. that acquire C. albicans 
infections. They have the greatest overall infection rate between 10-30% (Kojic & Darouiche, 2004). Our 
client statement was revised to not only incorporate Filastatin in a medical plastic, but specifically in a 
medical plastic that is used for urinary catheters. 
Objectives 
Our objectives stemmed from what was asked by our client as well as what was necessary to 
design a catheter comparable to those currently on the market. The client wanted Filastatin to be 
incorporated into the plastic and achieve a consistent decrease in cell adhesion with the incorporation 
method. Catheter manufacturers would want the incorporation method to be easy and cost effective 
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compared to what is already used and for it to work on a variety of catheter plastics. This information 
was then placed in an objective tree to outline what components defined success (Figure 5). 
 
Figure 5: Objectives Tree 
To rank our objectives in order of importance, they were organized into a Pair-wise Comparison Chart 
(PCC) by level. As seen in Table 2, the objectives were compared against each other and the final score 
was tallied to show its rank. 
Table 2: Pairwise Comparison Chart – Objectives 
 Incorporate 
Filastatin 
Decrease C. albicans 
adhesion 
Easy to incorporate in a 
manufacturing setting  
Versatility Score 
Incorporate Filastatin 
successfully 
X 1 1 1 3 
Decrease C. albicans 
adhesion 
0 X 1 1 2 
Easy/Cost effective to 
incorporate in a 
manufacturing setting 
0 0 X 1 1 
Versatility 0 0 0 X 0 
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 Indicated by the Pairwise Comparison Chart for the objectives, incorporation of Filastatin is the 
most important objective of this project. If the molecule cannot be combined into a plastic, then it 
cannot be used for urinary catheters. Filastatin is pigmented a vibrant yellow (Figure 6), and dyes the 
material yellow as well (Figure 7).  To quantify how much Filastatin is incorporated into the material; 
absorbance testing can be conducted at 400 nm wavelength in which Filastatin concentration related to 
absorbance is measured before and after incubation. 
 
Figure 6: Filastatin 25uM in Tris buffer  
 
Figure 7: Filastatin incorporated into silicone squares incubated in 25 uM Filastatin for 24 hrs. 
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The second highest ranking objective is to decrease C. albicans adhesion to the plastic compared 
to plastic without Filastatin. This is an important objective to the device’s success; however, 
incorporation directly affects the use of the molecule, while decreased cell adhesion describes the 
performance of the system. The highest incidence of healthcare-associated infection is associated with 
long-term indwelling catheterization (National Institute for Clinical Excellence (NICE), 2012). These 
indwelling catheterizations last on average 28 days, therefore our inhibition period should reflect that 
time period. Measuring cell adhesion to the material, will be conducted using a cell adhesion assays as 
described in the Project Approach Section later in this chapter to compare medical grade plastic with 
and without Filastatin incorporated. 
Next, ease and cost effectiveness to incorporate the molecule in a manufacturing setting was 
ranked. Having an economical solution to the design problem was ranked lower than the other two as 
the client is more concerned with having a functional device than a low cost design. In terms of 
manufacturing, the device should be cost effective. Cost effective means that the device should offset 
the cost of Candidemia to patients that acquire it.  
Lastly the versatility of the method on various plastics was ranked lowest because it is simply an 
addition that would broaden the usefulness of the device. Failing to meet this objective would not mean 
that we failed at meeting our client’s expectations. Versatility will be measured by testing Filastatin 
incorporation and cell adhesion for a variety of urinary catheter plastics using the same incorporation 
method. 
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Constraints 
There are two constraints our project must follow in order to meet our client’s needs and 
develop a useful design. Constraints serve as the boundaries for the design space and allow for the 
initial evaluation of design ideas.  
The most important constraint for our project, above all else, is to make sure the Filastatin 
incorporated urinary catheter is non-cytotoxic to humans. We know from previous experimentation that 
Filastatin is non-toxic through a human cell toxicity test (Fazly, 2013). In addition, the drug should work 
in urinary tract conditions. Urinary tracts are 37°C, constantly flushed, and can vary from slightly acidic 
to slightly basic. The pH of urine may range from 4.5 to 8 (Taylor et al., 1995) and have an average flow 
rate of 22.5 ml/sec (Kumar et al, 2009). 
Engineering Standards 
 In addition to parameters we created, there are medical device regulations that would need to 
be followed for this new device to be able to be marketed. The conventional and antimicrobial Foley 
catheters are described in the FDA regulations under 21 CFR 876.5130(a) (b), Urological Catheter and 
Accessories, as a class II device. It also falls under the scope of the ASTM F 623-89 standard as an 
indwelling catheter used by medical professionals to provide a means of bladder drainage. This standard 
describes the necessary testing procedures (outlined below). For testing purposes, special controls are 
not currently required under section 513. A catheter that is not within the scope of the ASTM F 623-89 
standard may merit special attention from the manufacturer as well as FDA. Lastly, ISO biocompatibility 
testing 10993 dictates that a cytotoxicity, systemic toxicity, mucosal irritation, sensitization and 
implantation testing be conducted for urinary catheters. 
Performance Data as outlined in ASTM F 623-89 
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1. The flow rate through the drainage lumen for each size  
2. The resistance of the balloon to rupture when inflated to the claimed balloon volume and held 
under conditions approximating the usage environment for a period of seven (7) days 
3. The resistance of the inflated balloon to being distorted and pulled through the bladder outlet 
4. The maintenance of balloon inflation to the labeled balloon volume over an extended time 
5. The manufacturing tolerances for the catheter tip, balloon, and shaft diameters 
6. The ability of an inflated catheter that has been submerged for 7 days to deflate reliably to 
within 4 Fr sizes of the labeled shaft size, including the time for such deflation; and 
7. Biocompatibility testing data for the materials of the device that may come in contact with 
human tissue (Outlined in ISO-10993). 
8. Data that demonstrates whether the active ingredient(s) cause any change in the make-up or 
specifications of the catheter and/or balloon; 
9. Shelf life/expiration date testing to demonstrate the effect of storage, adverse shipping 
conditions, and reprocessing (these effects should be reflected in labeling); 
10. Elution profile information to simulate and evaluate the release of the antimicrobial when 
exposed to body fluids 
11. In vitro test data characterizing the spectrum and degree of activity of the antimicrobial against 
all clinically important microorganisms (note: microorganisms should be clinical isolates, i.e., 
specimens derived from actual patient cultures). These microorganisms include: Candida 
Albicans, Citrobacter diversus, Enterobacter cloacae, Enterococcus, Escherichia coli, Klebsiellae 
pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus saprophyticus, and 
Streptococcus fecalis. The test sample should include the finished form of the device (e.g., 
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segments of the finished catheter). Note that if additional microorganisms are tested, 
justification, with supportive literature, should be provided for why they were tested; 
12. Detailed analysis of the potential for adverse effects such as the risk of superinfections; 
13. Information on the pharmacological and metabolic profile of the antimicrobial; 
14. Results from toxicity testing to assess the local and systemic effects of exposure to the 
antimicrobial 
15. Assessment of whether the antimicrobial concentration selected to elicit the desired 
prophylactic effect against clinically appropriate microorganism is optimal 
16. Results from a randomized, controlled clinical study to (a) demonstrate a clinically and 
statistically significant decrease in the rate of infection and at least comparable safety as 
compared to a legally marketed conventional Foley catheter, and/or clinically and statistically 
similar safety and effectiveness compared to an antimicrobial coated Foley catheter; (b) 
quantitate the degree of change of the infection rate per duration of use of the catheter; and (c) 
include data to support any additional claims, including reprocessing. 
17. Clinical information should also include: patient history of urinary tract infections (UTI) and all 
medications taken, urine cultures from patients and correlation of cultures taken from the urine 
sampled from collection bags, as well as the Foley tip for each patient in the control and 
experimental groups. Definitions and criteria for bacteriuria and UTI, as well as the urinary 
catheter care measures should be specified in the clinical protocol and be uniform across 
investigational sites. 
18. Laboratory testing should state whether test cultures used were derived from patient or 
laboratory isolates. 
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Functions 
There are two main functions this incorporation method will have: able to function as a urinary 
catheter and inhibit adhesion of C. albicans to the device. 
In order to ensure the device not only functions as a urinary catheter, but also inhibits the 
adhesion of C. albicans after incorporation of Filastatin has occurred, an in vitro simulation will be 
conducted. Once preliminary testing using the cell adhesion assay (See Appendix B) was performed with 
various types of incorporation methods, the most effective designs will move on to a longer assay that 
involves a low cell count to simulate in vivo physiological conditions in the human urinary tract and a 
longer incubation time. This is described in more detail in the Project Approach section.   
Project approach 
 The objectives and constraints, as outlined in the previous sections, guided the direction of this 
project. However, in order to fulfill these objectives while remaining within the confines of the 
constraints, an experimentation technique needed to be created. 
Incorporating Filastatin 
 As stated previously, Filastatin incorporation was measured using absorbance. Filastatin is a 
bright yellow molecule that has an absorbance of 400 nm. It was found that absorbance reading 
correlated linearly with concentration (R2 = 0.9897) (Figure 8). To determine how much Filastatin was 
being absorbed and eluted from the samples the team made serial dilutions of Filastatin. The first 
sample was at 25 uM and the final was 1.56 uM (See Appendix I). Based off of this correlation, 
approximate concentration could be determined. This was conducted in a 24-well plate in which plastic 
squares (0.8 x 0.8 cm.) were placed in 1.5 ml of 25uM Filastatin in Tris buffer. The plate was then placed 
on a rotator at roughly 80 RPM at room temperature and at various time points from 0 to 2880 min (2 
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days); 1 ml of solution was taken out and measured using a spectrophotometer at 400 nanometers. The 
1 ml of solution was put back into the plate each time and allowed to continue rotating. Absorbance 
readings were recorded in an Excel document and plotted against time. 
 
Figure 8: Absorbance versus Filastatin concentration standard curve 
Measuring Cell Adhesion  
We measured cell adhesion by testing C. albicans’ adhesion to plastic square and then catheter 
plastic of the same material (See Appendix B and Figure 9). The cells used for this experiment were 
SC5314 strain. This wild-type strain is more filamentous and more invasive than other wild-type strains 
of C. albicans (like VE175) and represent what would be most likely seen in a hospital (Hua et al., 2009). 
These cells were grown in supplemented YNB broth (Yeast Nitrogen Broth + 2 % glucose + 0.1 mg/ml 
uridine), in a 30oC shaker (Daniels et al., 2013).  In order to induce filamentation, spider media (1% Difco 
nutrient broth, 1% mannitol, 0.2% dibasic potassium phosphate, pH 7.2) was used and the cells were 
incubated at 37oC for 2.5 hours (Daniels et al., 2013).  
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 Samples were sterilized prior to cell seeding by immersion in ethanol followed by four doses of 
UV radiation at a radiant exposure of 3 mJ/cm2 based on literature (Dai et al., 2011). Certain 
incorporation methods needed different sterilization techniques, which is described in the Alternative 
Designs Chapter.  
Preliminary cell adhesion is the main focus of our assay because if we cannot prevent adhesion 
at short time points than it is unlikely that extended assays would be effective. Therefore, incubation 
was done for 2.5 hours because in the initial 0 to 3 hrs., the majority of C. albicans adhere to the surface 
(Chandra, Jyotsna, et al., 2001). We used 0.3 OD/ml (total 0.45 OD) of cells in reflection of a previously 
established cell seeding experiment on silicone elastomers that had even distribution of cells on the 
surface (Chandra, Jyotsna, et al., 2001). An Optical Density (OD) reading of 1.0 for C. albicans suspension 
at 600 nm wavelength is approximately 3 x 107 cells.  
One method for quantifying cell number is a Crystal Violet assay. Crystal violet is a 
triarylmethane dye that stains DNA within cells and has an absorbance around 590 nm (Adams and 
Ludwig, 1914). After incubating cells with crystal violet for 15 minutes, the samples were submerged in 
acetic acid to remove the stain from the sample. Absorbance readings were taken in duplicate to 
measure the approximate number of cells in the sample.   
Another method for quantifying cell number is through an Alamar Blue assay. Alamar blue is a 
cell permeable indicator for metabolic cell function (Räz et al., 1997) Resazurin, the active ingredient of 
AlamarBlue® reagent, is a non-toxic compound that is blue in color and virtually non-fluorescent. Upon 
entering cells, resazurin is reduced to resorufin, a compound that is red in color and highly fluorescent. 
Viable cells continuously convert resazurin to resorufin, increasing the overall fluorescence and color of 
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the media surrounding cells (Räz et al., 1997). Readings are done at an excitation of 555 and emission of 
585 (555Ex/585Em) after a one-hour incubation period. 
 
Figure 9: Basic methodology of the cell adhesion assay 
When data was acquired (either fluorescence or absorbance) outliers were identified using 
Tukey’s boxplot (Rousseeuw, 2011). Box-plots take the interquartile distance from the upper and lower 
quartiles of data and multiples it by 1.5 (1.5*IQR). The interval or “fence” is defined as the upper 
quartile plus 1.5*IQR and the lower limit minus 1.5*IQR. Any values outside this range were rejected. 
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The most outliers that was ever reject was 2 out of 12 readings per a condition (only occurred twice). 
The computations for this were carried out using Excel.  Next, background was subtracted from the 
readings. Background was a control that measured either the fluorescence or absorbance of the dye 
itself when no cells were present. In addition, we found that the growth of cells during the cell adhesion 
assay was slightly different from experiment to experiment. In order to be able to compare each 
experiment to one another, we later normalized the data to the uncoated control square. Next, the data 
was plotted as a mean ± standard deviation. Lastly, a p-test or ANOVA test was conducted to test 
statistical significance or difference between different conditions or sets of conditions, respectively. 
Longer term simulated in vivo testing 
 After preliminary cell adhesion testing is conducted (short term 2.5 hr. reading with 0.3 OD/ml 
cells), a more physiologically accurate testing was conducted with the incorporation methods that 
worked effectively. The initial cell count used was 1000 cells per mL, or 0.0001 OD/mL. This cell count 
was chosen to more closely simulate the number of cells found in vivo (Achkar and Fries, 2010). The 
experiment otherwise was set up similarly to what was done for the 2.5 hr incubation studeis. After 22 
hours and 45 hours of incubation, samples were extracted and processed. An OD measurement was also 
taken for each condition as well as morphological pictures.  
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Chapter 4: Alternative Designs 
We generated four alternative designs for Filastatin incorporation into medical plastics based on 
previous research (See Prevention: Current Antifungal Materials Section). The four alternatives are 
polymerization, functionalizing agent, absorption, and entrapment.  
Polymerization 
 As discussed in Chapter 2, polymerization is one method used to incorporate antifungal agents 
into the medical material. At the start of the project, our client had already developed thiolene network 
polymers with Filastatin incorporated into them with the help of collaboration at the University of 
Massachusetts: Lowell (Umass Lowell) (Figure 10). This involves suspending 50mM Filastatin in 1% 
DMSO (an organic solvent used in previous studies (Fazly et. al., 2013)) and blending the compounds 
with the thiolene network in a melt state and curing to form a 3 mm thick sheet (2.54 cm x 5.08 cm). By 
blending these compounds, they were able to induce the formation of tough, robust polymer networks 
via thiol-ene chemistry (Lowe, 2010). Thiol-ene chemistry involves the reaction of thiol (-SH) groups with 
carbon-carbon double bonds (C=C), as shown in Figure 11. 
  
Figure 10: Conceptual design of Thiolene network polymer with Filastatin polymerized 
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Figure 11: The thiol-ene reaction by which the polymeric infusion proposed was formed. This 
reaction is rapid, involving low toxicity liquid reagents and requiring no solvent, initiator, or other 
additives. 
 Umass Lowell has demonstrated that this effort is feasible for Filastatin because 
thermogravimetric analysis (TGA) confirms its stability over the temperature range relevant for melt-
processing of the thermoplastics of interest (~150-250°C) in both inert atmosphere and air (Figure 12). 
Differential scanning calorimetry data (not provided by UMass Lowell) indicated a clean melting 
transition at ~143°C with no evidence of degradation, confirming that this compound will be a thermally 
stable liquid amenable to rapid blending with molten plastics. 
The melt-blending work was carried out using a Technovel 15mm lab-scale twin-screw extruder. 
The unit was heated to the appropriate temperature for extrusion processing and the polymer was melt-
blended and extruded as a thin sheet via a custom-made sheet die, either alone or mixed with the 
compound of choice. As Filastatin is a colored compound, optical microscopy will allow for visualization 
of any large-scale variations in concentration. In addition, the quantification of the total compound 
concentrations was carried out via laser scanning confocal fluorescence microscopy (LSCFM). 
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Figure 12: Filastatin shows sufficient thermal stability for blending with molten thermoplastics. 
Thermal stability was assessed in both air and N2, heating at 20°C/min from room temperature to 
1000°C. Melt temperatures for the medical plastics of interest here do not exceed 250°C. (This graph was 
provided by UMass Lowell) 
 Six Thiolene- network squares with Filastatin (0.8 x 0.8 cm), six thiolene-network squares 
without Filastatin and six control wells with only water and Alamar blue was used to measure cell 
adhesion assay (See Appendix B). Fluorescent signals at 555Ex/585Em were measured using a 
SpectraMax M5 Plate reader (Molecular Devices) (See Appendix C for more details). The signals were 
averaged and graphed in Figure 13 below: 
 
Figure 13: Normalized fluorescence values of Alamar blue cell adhesion assay using polymerization method 
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The Thiolene network with Filastatin and Thiolene network without Filastatin were not 
significantly different from one another (p-value of 0.8672). We believe this was due to Filastatin not 
presented properly on the surface of the polymer. If the section of Filastatin that is crucial to stopping 
hyphal formation is bound to the thiolene network, then it may not effectively inhibit C. albicans 
adhesion.  
Using a Functionalizing Agent 
Since polymerization did not seem to produce an inhibiting effect, we hypothesized that 
presenting the molecule on the surface of the material would allow better interaction between 
Filastatin and the cells. In order to accomplish this, we functionalized the surface using an organic 
tether. 
At this point in the project, we were able to receive medical grade silicone plastic from Bentec 
Medical Inc. (REF PR72034-04N). We decided to use the organic tether (3-Aminopropyl) triethoxysilane 
(APTMS) (Figure 14 & 15). This decision was based on the fact that silanization of APTMS and silicone 
forms a strong covalent bond. The silicone was cleaned using oxygen plasma. This was a different 
cleaning procedure compared to other alternative designs because APTMS requires a completely clean 
surface, free of organic residues, in order for the APTMS molecule to bind properly in its correct 
orientation and create an even coating on the surface (Seu et al., 2007). The clean squares were soaked 
in a 10% APTMS solution for 12 hours before being sealed in a sterile Petri dish. Successful incorporation 
of Filastatin was found using absorbance differentiation, as described previously (Figure 16). Six 
technical replicates were used per sample.  
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Figure 14: APTMS molecule 
 
Figure 15: Conceptual Design of using a functionalizing agent (APTMS) 
  
Figure 16: Concentration of Filastatin in solution as it is bound onto silicone functionalized with APTMS 
The squares were then tested via the cell viability assay (6 squares per condition) using crystal 
violet as opposed to Alamar blue due to our findings that showed it to be not only be a more precise 
dye, but also faster (See Appendix D). Crystal violet was used for the rest of experimentation moving 
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forward. Results are shown below in Figure 17 (See Appendix E for details). The conditions included an 
uncoated silicone square to normalize values to and provide a negative control, a silicone square with 
APTMS attached to ensure that APTMS in itself did not decrease cell adhesion, a silicone square with 
APTMS attached and then Filastatin attached, an uncoated silicone square coincubated with soluble 
Filastatin as a positive control and an uncoated silicone square with no cells used for background 
absorbance of crystal violet that is absorbed by the silicone itself.  
 
Figure 17: Normalized absorbance values of Crystal Violet cell adhesion assay using functionalizing agent method 
When Filastatin was co-incubated with spider media, cells and the silicone squares, there was a 
decrease (55% relative to uncoated silicone) which showed that the molecule did indeed work in 
solution as seen in previous literature. Our uncoated silicone control ended up being not statistically 
different from the silicone with APTMS treatment, as well as the silicone with APTMS treatment with 
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Filastatin attached based on an ANOVA test (p>0.05). The APTMS treatment did not inhibit cell adhesion 
significantly compared to the controls. This may be due to poor presentation of the molecule to the 
cells. This led to our next design that involved the release of the molecule, as opposed to binding.  
 
Absorption 
 Our alternative to a functionalizing agent was absorption (Figure 18). Absorption was done by 
incubating the silicone squares in a 25uM Filastatin solution overnight (Fazly et al., 2013).  The rationale 
behind absorption was to allow the Filastatin to leak out of the silicone because we knew that in 
solution Filastatin was effective at inhibiting the adhesion of C. albicans cells. Successful incorporation of 
Filastatin was found using absorbance, as described previously (Figure 19). 6 technical replicates were 
used. In addition, the Filastatin was identified throughout the square. When it was cut in half, the yellow 
color was present in the center as well as the surface. 
  
Figure 18: Conceptual Design of Absorption 
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Figure 19: Concentration of Filastatin in solution as it is absorbed into silicone 
The cell adhesion assay was carried out with 6 technical replicates of an uncoated silicone 
square, a Filastatin absorbed square, an uncoated silicone square co-incubated with soluble Filastatin, 
and an uncoated square control that had no cells. Results are shown below in Figure 20 (See Appendix F 
for more details). 
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Figure 20: Normalized absorbance values of Crystal Violet cell adhesion assay using absorption method 
The experiment showed a clear decrease in cell adhesion for the absorbed Filastatin squares and 
the uncoated coincubated in soluble Filastatin of around 60% +/- 5% relative to the control uncoated 
square. In addition, there was no statistical difference between the absorbed squares and co-incubation 
squares (p>0.05). This shows that this method was just as effective as the molecule in solution.   
Entrapment 
 Another alternative design was entrapment through polydopamine (Figure 21). Polydopamine is 
a self-polymerizing non-toxic molecule that forms thin, surface-adherent films on a wide range of 
inorganic and organic materials (Ding et al., 2012) and studies have shown that it is a promising slow-
release mechanism. For this incorporation method, 2 g/ml of polydopamine in 10 ml of 10mM of 8.5 pH 
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Tris was used to create a film over the already absorbed Filastatin using the same method. Successful 
incorporation of Filastatin was already found in the previous experiment (Figure 19). 
  
Figure 21: Conceptual Design of Entrapment 
The cell adhesion assay was carried out with 6 technical replicates of uncoated silicone square, 
polydopamine coated square to see if polydopamine itself had effect on adhesion, Filastatin absorbed 
then polydopamine coated square, Uncoated coincubated in soluble Filastatin in the solution with the 
square, and a control that had no cells. Results are shown below in Figure 22 (See Appendix G for more 
details) 
 
Figure 22: Normalized absorbance values of Crystal Violet cell adhesion using entrapment method 
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Interestingly, polydopamine by itself had around a 51% decrease in cell adhesion. This could be 
associated with it creating a hydrophobic layer on the surface that prevents adhesion of cells (Sileika et 
al., 2011). In addition, the experiment showed a decrease in cell adhesion for the absorbed Filastatin 
then polydopamine squares of around 76% relative to the control uncoated square.  
Conclusion 
Based on the results from the preliminary screening, both absorption of Filastatin and 
entrapment through a polydopamine film showed a decrease in C. albicans adhesion, while using a 
functionalizing agent or co-polymerization did not. The alternative designs that did not work were not 
pursued moving forward and we focused on the designs that showed promise. These incorporation 
methods moved on to be further tested two more times and at longer incubation times with fewer cells 
to prove its effectiveness. In addition, the squares were changed to catheter segments to better 
simulate the shape that the cells would be adhering to. 
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Chapter 5: Design Verification 
Included in this chapter are the results of the experiments performed using the incorporation 
methods that passed the preliminary screening. These experiments include repeating validated studies 
with multiple replicates, testing the versatility of the incorporation method, calculating the elution rate, 
testing with catheters, forecasting approximate cost per catheter for each incorporation method, and 
finally a 22 and 45 hr. testing with lower cell concentration. 
Reaffirming effectiveness with multiple replicates 
A crystal violet assay, as described in Project Approach, was the measurement for the second 
objective: preventing C. albicans’ adhesion. As stated above, cell growth and adhesion varied from one 
replicate to the next. In order to be sure that the results of Filastatin incorporation and inhibition of cell 
adhesion were consistent, this assay was repeated on three separate occasions. Figure 23 shows that 
incorporating Filastatin was consistently effective in inhibiting C. albicans’ adhesion (See Appendix H). 
Each condition was replicated 3 times with 6 replicates of each condition. 
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Figure 23: Normalized absorbance values of Crystal Violet cell adhesion assay on Silicone Squares 
 The results showed that based on an ANOVA test, all conditions that decreased cell adhesion 
were not statistically significant from one another (p = 0.841). All conditions decreased cell adhesion on 
average by 49±6%. 
Calculating elution rate 
 Since we knew that Filastatin was being successfully absorbed into the samples, we wanted 
determine if Filastatin was then being eluted out from the material. To determine how much Filastatin 
was being absorbed and eluted from the samples the team used the standard curve described 
previously (Figure 8). The equation for the trendline was used to calculate Fialastatin’s concentration in 
solution as it was absorbed and then eluted from the samples.  
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Figure 19 showed in Chapter 4: Alternative Designs presented how much Filastatin that 
absorbed into silicone squares over two days (See Appendix J for details). The concentration of Filastatin 
in Tris (pH 8.5) plateaued around 3uM. Six samples were placed into six wells of a 24 well polystyrene 
plate. The samples were submerged into 1.5mL 25uM Filastatin in 10 mM Tris pH 8.5, 1% DMSO.  The 
amount of Filastatin incorporated into the samples was calculated by measuring the absorbance of 
Filastin at 400 nm over the course of two days. During the first two hours the six samples varied greatly. 
The samples’ absorption began to converge after 24 hours, and by 48 hours was within 0.001 of each 
other. The final Filastatin concentration was roughly 0.03uM; the samples had each taken up 8.8 ng 
(25uM = 1.5 ul Filastatin (aq) in 1.5 ml Tris buffer = 10 ng Filastatin (s) (Fazly, 2013); therefore 
(22uM/25uM) * 10ng = 8.8 ng). 
Once the samples had reached the maximum absorption of Filastatin they were moved to a 
fresh plate with 1.5 mL 10mM Tris pH8.5. The absorbance of each sample was read at 400 nm over four 
days (Figure 24). Samples with Filastatin absorbed were compared to those coated in polydopamine 
after being absorbed in Filastatin to determine that entrapment method created a slow release of 
Filastatin. 
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Figure 24: A) Absorbance of Filastatin eluted from silicone B) Absorbance of Filastatin eluted from 
silicone entrapped in polydopamine 
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Time points between zero and 720 minutes created roughly linear elution rate of 0.833 
nanomoles per hour for the silicone squares and 1.08 nanomoles per hour for squares coated in 
polydopamine after Filastatin (See Appendix K for details).  This was not a signifcant difference. In 
addition, the amount of Filastatin released both reached a maximum release of 0.03 uM Filastatin at the 
same time point of 96 hrs.  This may not be the saturation point of Filastatin in silicone, but rather 
appears to be the point of equilibrium between the solution and silicone samples based on the fact that 
the absorption testing also reached the point of 0.03 uM of Filastatin left in solution. 
Testing the versatility of the incorporation method 
The third objective was to develop incorporation methods that could be used on different 
catheter plastics. Two catheter plastics available at the University of Massachusetts Medical School were 
thermoplastic polyurethane and pellethane. Both of these plastics were acquired from Bentec Medical. 
They were comparable to silicone in rigidity and opacity. The major difference between the materials  is 
that Pellethane swelled more than thermoplastic polyurethane or silicone. Despite these changes, 
Filastin incorporation did not affect cell adhesion onto these plastics. Based on an ANOVA test, there 
was no noticeable change in cell adhesion throughout the experimental conditions for Pellethane 
(Figure 25) (See Appendix L for details). There was some effect with soluble Filastatin, but not as much as 
it was on silicone (67±10% vs.26±17%). Figure 26 shows that the Filastatin absorbed and polydopamine 
coated were statistically similar compared to the uncoated control, meaning these conditions did not 
have an effect. Combined effects of Filastatin and polydopamine were slightly less compared to the 
uncoated control, but the decrease (28±7%) was not as much as it was on silicone (65±16%) for 
thermoplastic polyurethane (See Appendix M for details).  In addition, the percent decrease of Uncoated 
coincubated in soluble Filastatin was also lower (67±10% vs.40±6%).  
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Figure 25: Normalized absorbance values of Crystal Violet cell adhesion assay on Pellethane 
 
Figure 26: Normalized absorbance values of Crystal Violet cell adhesion assay on thermoplastic polyurethane 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Uncoated Polydopamine
coated
Filastatin
absorbed
Filastatin
absorbed then
Polydopamine
coated
Uncoated,
coincubated
with soluble
Filastatin
No cells
N
o
rm
al
iz
e
d
 a
b
so
rb
an
ce
 v
al
u
e
s 
at
 5
9
0
 n
m
* = p > 0.05
*
26±17%↓
0.45 OD cells seeded; 2.5 hr. incubation N = 1 experiment, 6 replicates
0
0.2
0.4
0.6
0.8
1
1.2
Uncoated Polydopamine
coated
Filastatin
absorbed
Filastatin
absorbed then
Polydopamine
coated
Uncoated,
coincubated
with soluble
Filastatin
No cellsN
o
rm
al
iz
e
d
 A
b
so
rb
an
ce
 v
al
u
e
s 
at
 5
9
0
n
M
* = p > 0.05*
28±7%↓
N = 1 experiment, 6 replicates0.45 OD cells seeded; 2.5 hr. incubation
* 
* 
40±6%↓ 
* 
* 
* 
53 
 
Switch to catheters 
 Incorporating Filastatin into silicone via absorption worked with and without polydopamine. The 
silicone used in the previous assays was a sheet and the next step was to test a catheter material using 
the same assay. The catheter was made of a similar silicone from Seeking Health™ with an outer 
diameter (OD) of 11 mm and inner diameter (ID) of 8 mm. When testing this catheter, two options for 
cutting were tried including rings and curved squares. Rings were cut to a depth of 2mm and curved 
squares were cut 8 x 8 mm. Rings were chosen over curved square segments due to inconsistent square 
size because of difficulty cutting as well as significantly different readings compared to what was seen in 
the sheets even within the same assay. Figure 27 shows that the rings had a greater decrease in cell 
adhesion (59±11%), comparable to the silicone squares (49±6%) (See Appendix N for details).  
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Figure 27: Normalized absorbance values of Crystal violet cell adhesion assay done with both A) circular 
cross section (rings) and B) lateral bi-section (curved squares) 
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Once a proper cutting style was determined, three assays were done to find the average 
decrease for each incorporation method. The results are shown in Figure 28. Although the rings were 
not always exactly the same shape (some were lopsided), they were weighed to assure that size was 
equal by mass. 
 
Figure 28: Normalized absorbance values of Crystal violet cell adhesion assay on silicone catheter rings 
All of the experimental conditions, similarly to the silicone sheet, were not statistically different 
from one another (p = 0.6427) (See Appendix O for details). The overall decrease in cells that adhered to 
the surfaces was 58±4%. 
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Cost Analysis  
 Our last objective was to understand the monetary value of the incorporation method by 
creating a cost analysis to estimate how much it would cost to produce one full catheter with the 
absorption of Filastatin and Filastatin absorbed with a polydopamine layer. The following was used for 
the absorption of Filastatin: 
Cost of Filastatin per 1 ul ($/ul) 
25mg of Filastatin = $297.50 (Sigma Aldrich)  
Soluble in DMSO at 10 mg/mL 
(10 mg / 25mg) * $297.50 = $119.00 per 1 ml (1000 ul) 
$119.00 / 1000ul = $0.119/ul 
Volume of catheter section used in experimentation 
1 Silicone catheter ring = 11mm outer diameter (OD) x 8mm inner diameter (ID) x 2mm tall 
Volume of a tube was calculated by taking the volume of the outer diameter and subtracting the volume 
of the inner diameter. 
Volume outer = (5.5)2 * π * 2 = 190.066 mm3 
Volume inner = (4)2 * π * 2 = 100.521 mm3 
Volume total = Vout-Vin= 89.545 mm3 
Volume of typical catheter (BARD medical© Uncoated Silicone Foley Catheters 12 FR 14”) 
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1 Full Catheter = 4 mm outer diameter (OD) x 2.3mm inner diameter (ID) x 355.6mm tall 
Volume of a tube was calculated by taking the volume of the outer diameter and subtracting the volume 
of the inner diameter. 
Volume outer = (2)2 * π * 355.6 = 4468.601 mm3 
Volume inner = (1.15)2 * π * 355.6 = 1477.431 mm3 
Volume total = Vout-Vin= 2991.17 mm3 
Total volume of catheter section / Total volume of full catheter 
2991.17 mm3 / 89.55 mm3   = 33.402 
Amount of Filastatin needed for a full catheter proportionally 
33.402 * 1.5 ul (Filastatin in DMSO used for 1 catheter section) = 50.103 ul (for 1 full catheter) 
Total cost of 1 full catheter coating 
50.103 ul * $0.199/ul = $9.97 
The following was used for the polydopamine coating: 
Cost of Polydopamine per 1 g ($/ul) 
Polydopamine 100g = $318 = $3.18/gram (Sigma Aldrich) 
Amount of Polydopamine needed for a full catheter based off proportion 
33.402 * 0.00666 g (Polydopamine used for 1 catheter section) = 0.223(for 1 full catheter) 
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Total cost of 1 full catheter coating 
0.223 * $3.18/gram = $0.71 
The total cost of treating a silicone catheter with Filastatin would be about $9.97 and with the 
addition of a polydopamine layer, it would cost $10.68.  
Testing long-term  
 After adhesion testing for 2.5 hrs. with catheter segments was done to assess the effectiveness 
of each incorporation method, a longer assay was conducted using a lower starting cell count (1000 cells 
or 0.0001 OD) and ran for 22 hrs. and 45 hrs. The experiment was conducted similarly to the original 
assay and was completed to more accurately simulate a C. albicans infection (Achkar and Fries, 2010). 
The 22 hr. reading was done twice with 6 technical replicates (See Appendix P for details), while the 45 
hr. was done once with 6 technical replicates (See Appendix Q for details). The OD of cells reached 0.217 
+/- 0.017 or ~ 6 x 106 cells at 22 hrs. and 1.55 +/- 0.136 or ~ 4.65 x 107 cells at 45 hrs. Results are shown 
in Figure 29 and Figure 30. 
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Figure 29: Normalized absorbance values of Crystal violet cell adhesion assay on silicone catheter rings (22 hrs.) 
 
Figure 30: Normalized absorbance values of Crystal violet cell adhesion assay on silicone catheter rings (45 hrs.) 
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 Interestingly, polydopamine coated and Filastatin absorbed then polydopamine coated was not 
effective at preventing C. albicans adhesion and in fact helped attachment. At 22 hrs., Filastatin 
absorbed and soluble Filastatin showed statistically significant decrease in cell adhesion (51±1% and 
33±6% respectively). At 44 hrs., the conditions again showed significant decrease in cell adhesion, and 
even more so in the Filastatin absorbed conditions (81±5% and 60±6%, respectively). The cell adhesion 
to Filastatin absorbed samples was not statistically different compared to the no cells negative control.  
This is further represented in the morphological pictures obtained to visualize see the effect each 
conditions was having on the cells attached to the segment of catheter (Figure 31-36). 
     
Figure 31: Uncoated at 22hrs. and 45 hrs. 
     
Figure 32: Polydopamine coated at 22hrs. and 45 hrs. 
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Figure 33: Filastatin absorbed at 22hrs. and 45 hrs. 
     
Figure 34: Filastatin absorbed then Polydopamine coated at 22hrs. and 45 hrs. 
     
Figure 35: Soluble Filastatin at 22hrs. and 45 hrs. 
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Figure 36: No cells at 22hrs. and 45 hrs. 
The morphological pictures showed hyphal formation and many cells in polydopamine coated and 
Filastatin absorbed then polydopamine coated conditions. Uncoated had fewer cells in comparison to 
the polydopamine associated conditions, but more than the Filastatin conditions and increased from the 
22 hr. to the 45 hr. time period. Soluble Filastatin showed few cells and little to no hyphal formation at 
22 hrs., but at 45 hrs., there was an increase in the amount of cells and slightly more hyphal formation. 
The Filastatin absorbed showed little to no hyphal formation and cells. 
 
 
 
 
 
200um 
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Chapter 6: Discussion 
 Over the past seven months the team was able to design and test alternatives for Filastatin 
incorporation to decrease C. albicans’ ability to adhere to silicone. Preliminary testing with a starting OD 
of 0.45 or 1.5 x 107 cells and short incubation (2.5 hrs.) showed that two of the four incorporation 
alternatives (absorption and entrapment) were effective at preventing C. albicans adhesion with both 
silicone sheets and catheter segments. Conversely, repeated experimentation with longer incubation 
(22 and 45 hrs.) and lower starting OD (0.0001 or 1000 cells) displayed that only Filastatin absorbed was 
effective, while entrapment appreared to improve cell attachment. From this data and morphological 
imaging, we believe that the polydopamine may have encapsulated cells (shown in Figure 37 & 38 as 
black spots), thus having a greater amount of cells adhered compared to the uncoated control.    
 Outlier testing using Tukey’s boxplot was applied to each data set. These outliers were likely to 
be due to too inconsistencies in washing of the silicone squares after crystal violet treatment or poor cell 
growth during incubation period. Outliers were mathematically identified and excluded from the data 
because they did not represent the entirety of the set. 
The team was unable to replicate the incorporation methods using materials other than silicone. 
Tests on thermoplastic polyurethane and Pellethane showed insignificant decreases in cell adhesion. 
These results may be in part due to the cell quantification assays used; crystal violet and Alamar blue 
both stained the Pellethane squares. The thermoplastic polyurethane squares showed even cell 
adhesion across each condition except for co-incubation with Filastatin.  
 The team’s incorporation method was also easily manufactureable compared to what is 
currently on the market. Filastatin incorporation was done by soaking the sample in 25 uM Filastatin 
overnight. This method worked for both silicone sheets and rings of an on-market catheter. This method 
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has three steps. Filastatin must be dissolved in DMSO, this solution is added to Tris buffer as specified 
above, and the silicone is left in the solution overnight.  
 Lastly, the incorporation method costs $9.97. This is more cost effective compared to what is 
currently on the market and the price of impact Candidema has on a catheter to patients that acquire it 
(See calculation below).    
𝐶 +  𝑇(𝑃) 
C = Cost of average catheter 
T = Cost for treatment of Candidemia cases caused by catheters 
P = Percentage of catheterizations that cause Candidemia 
 
The cost of a typical urinary catheter (Foley Catheter) is $1.29 (Pickard et al., 2012), the average 
cost of treatment of Candidemia per patient is $758 (Edwards, 2009), and the percentage of 
catheterizations that cause Candidemia is about 3% (Kojic, 2004). This results in a cost of the device of 
$24.03. Anything more than this price would not outweigh the impact Candidema has on a catheter to 
patients that acquire it.  Based off of our objectives, the cost of our proposed incorporation method 
would not exceed this amount of $24.03 per catheter. In addition, antimicrobial silver hydrogel 
catheters on average cost about $10.58 (Pickard et. al, 2012). The cost of this catheter is comparable 
with ours and would allow our catheter to compete. Finally, these estimates can be assumed to be even 
lower with manufacturing because the chemicals would be bought in bulk.   
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Analysis and Limitations of Experiments 
The experimentation limits stem from lack of time and material. The team only had access to 
two alternative materials to test incorporation designs. Replication of assays  on silicone materials was 
prioritized over ordering additional materials. The team was also not able to repeat the longer assay at 
farther time points. Lastly, the team did not properly imitate in vivo conditions.  
 The outlying limit for the team was understanding Filastatin. As a new molecule its functions 
and chemistry are not clearly defined. The team did not understand its interaction with cells: whether 
Filastatin interacts with cell receptors or must be metabolized to be effective. 
Impact Analysis 
 The design team analyzed the global impact of this product. The team considered how the 
antifungal catheter would perform in terms of economics, political ramifications, environmental impact, 
manufacturability, sustainability, societal influence, ethical concerns, and health and safety issues. 
Economics 
As stated in the beginning, the estimated annual cost of treating a systemic C. albicans infection 
exceeds 200 million dollars per year due to its increasing resistance to antifungal drugs (Millar et. al, 
2001). Based on our results, our device not only prevents the cost of treatment, but also the device 
would have an equivalent cost on the medical device industry to what is currently on the market in 
terms of preventative antimicrobial devices (See Cost Analysis section).  In general, the economic and 
social impact of microbial infection in our society supports the need for new antimicrobial methods that 
are effective.  
66 
 
Environmental Impact 
 The majority of this product’s impact on the environment stems from the manufacture of 
laboratory plasticware required to produce the catheter. Furthermore, any waste produced during 
fabrication will be considered biohazardous and will have to be properly disposed.  Finally, the 
manufacturing facilities will require more power (natural resources) to add an additional step to 
catheter construction to incorporate Filastatin.  One positive environmental point to the design choice is 
that the solvent that is used to suspend Filastatin is a nontoxic organic solvent that has been used in 
pharmaceutical synthesis, the manufacture of electronics, and drug delivery in the body (Simon, 2009). 
In addition, it actually occurs naturally in small doses in the environment. 
Social Influence 
 There could be a possible social drawback because of the coloration of the Filastatin. Filastatin is 
a bright yellow molecule that stains the catheter the same color. A yellow catheter versus one that is 
clear or white could make the yellow catheter seem unclean and be off putting to sales and patient use 
of the product. On other hand, if a person had to choose between a normal catheter and one that is 
antifungal, they would be most likely to choose the one that will be more preventative (Staff, 2001).  
Political Ramifications 
 The global antimicrobial coatings for medical devices market is estimated at USD 0.61 Billion in 
2015, and is projected to reach USD 1.17 Billion by 2020, at a CAGR of 14.2% during the forecast period 
(Grand View Research, 2016). Factors such as rising awareness about hospital-acquired infections, 
favorable research and funding environment, technological advancements in antimicrobial coatings, 
growing implantable devices market, and increasing research and development activities for 
antimicrobial coated devices are driving the growth of this market. However, factors such as limitations 
of silver coatings, presence of time and resource intensive processes for development and approval of 
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antimicrobial coating products, and unfavorable health care reforms in the U.S. are hindering its market 
growth.  
Ethical Concerns 
To validate the successful, therapeutic product, of our catheter, we will have to undergo 
multiple animal trials before it can be tested in clinical trials. Scientific testing on animals has brought 
forth many ethical concerns; proper animal care and scientific protocol must be followed according to 
the Institutional Animal Care and Use Committees standards. The animals must have living conditions 
that are appropriate for their species, and procedures should minimize discomfort and pain, using 
methods of euthanasia only when appropriate.  
Health and Safety Issues 
Our catheter addresses the limitation of infections that affects many surgical procedures. 
Hospitals have struggled with procedure-induced infections, and the surgery makes urinary tracts most 
susceptible. The addition of a defense mechanism against infection built into this catheter will further 
protect the patient’s health and allow for better healing. The safety of this scaffold will be determined 
through multiple animal and clinical trials according to FDA regulations. 
Manufacturability 
 The manufacture of this device would be simplistic. Silicone catheters would be incubated 
overnight in a vat of Filastatin at a concentration of 25uM and washed the next day. The exact 
procedure can be tweaked to optimize its production and create a consistency from catheter to 
catheter. 
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Sustainability 
 Because the catheter uses drug elution, its antifungal activity is limited to how much Filastatin 
can be absorbed into it. This is not a very sustainable process because eventually the Filastatin will run 
out. However, once the molecule is incorporated into the material, only minimal energy is required to 
store the product until usage. If operations for the disposable resources were to use renewable energy, 
the process would become much more sustainable and would not have a major negative impact on the 
biological/ecological environment.  
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Chapter 7: Final Design and Validation 
The device was developed through preliminary screening of the various design concepts and 
incorporation methods. Using the allotted time and material resources, the most effective methods, 
absorption and entrapment, were further analyzed with catheter segments and put through more 
physiologically accurate testing with a long-term incubation. After this testing, Filastatin absorbed 
proved to be the best method and our final design selection. Our methodology for administering this 
evaluation is outlined below (Figure 37) and the following sections detail the process.  
 
Figure 37:  Final design approach 
Part 1: Preliminary screening 
 Incorporation methods were tested using a cell adhesion assay to compare its effectiveness 
against a control, unaltered material. First, samples were cleaned using 100% ethanol and 4 does of 
3000 µJ/cm2  UV radiation (APTMS functionalized samples were cleaned with oxygen plasma). Then 
Filastatin was incorporated using the appropriate method (polymerization, organic tether, absorption, 
entrapment). Next, samples were incubated with an overnight culture of C. albicans in spider media at 
37*C 80 RPM. After a 2.5 incubation period, samples were washed three times with deionized water and 
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cells adhered to the surface were quantified using either crystal violet or Alamar blue. For the crystal 
violet dye, samples needed an additional washing after followed by submersion in acetic acid to the 
remove the dye before it was measured in a 24-well plate. Data was put through outlier (at most 2/12 
readings) and background removal and normalized to the control, unaltered material. The results were 
then analyzed for statistical significance using a p-test, as well as a ANOVA test. Those that were 
statistically dissimilar moved on to physiologically accurate testing. 
Part 2: Physiologically accurate testing 
 Physiologically accurate testing involved the use of a lower cell count (1000 cells) and the use of 
longer time course (22 and 45 hrs. of incubation) to simulate in vivo conditions. The assay was carried 
out similar to the preliminary screening. The results were analyzed again using the same statistical 
methods. 
Part 3: Final design selection 
 The data from the physiologically accurate testing was put through identical analysis to 
preliminary screening and the final design was chosen based on effectiveness (Filastatin absorbed) 
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Chapter 8: Conclusions and Recommendations  
The following discussion presents recommendations for overcoming our project limitations as 
well as future methods for realizing the successful production of our antifungal catheter.  
Recommendations 
Through the various experiments, the team was able to determine which methods work best for 
our design and modifications we would make to improve the project. The following are 
recommendations that we advise in order to better the design and validation testing. 
Urine pump with artificial bladder & ureter 
 A dynamic model that simulates the lower urinary tract has been developed in order to evaluate 
antibacterial urinary catheters. One model consists of an artificial simulated bladder made out of a 
fermentation flask placed in an incubator at 37°C, with a urinary catheter attached to its lower outlet to 
mimic a urethra (Wang et al., 2015). Artificial urine with a culture of C. albicans in a sealed glass 
container would be pumped into the simulated bladder at a rate of 0.5 ml/min then allowed to flow out 
through the catheter. Catheter pieces would then be collected over a month period and our cell 
adhesion assay could be conducted (dye portion). The described in vitro dynamic model of a 
catheterized bladder enables us to emulate many of the characteristics of a catheterized human bladder 
in the absence of a bladder epithelium. Unfortunately, due to time constraints and financing for the 
specialized fermentation flask, we were not able to perform these tests. 
Standardizing cell count for the overnight culture 
 When we were first started to create a cell adhesion assay, we experienced difficulty getting 
consistent data from experiment to experiment. We hypothesized that this was associated with the 
overnight culture. Originally, we took a colony of C. albicans from an YPD (yeast extract peptone 
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dextrose) plate and dropped it into a solution of supplemental 0.2% glucose YNB (yeast nitrogen base) 
media. The next day we read the O.D and extract the amount of cells necessary to complete the 
experiment. What we found was that 10 OD/ml or greater resulted in C. albicans that were in death-
phase, while 5-7 OD/ml had enough cells to complete the experiment and keep them in log-phase 
(Figure 38). Therefore, we came in later the same night of setting up the overnight culture and adjusting 
the cell count to have 5-7 OD/ml the following day. 
  
Figure 38: Comparison of overnight cultures effect on cell adhesion assay  
Creating samples identical replicates 
 Another difficulty that came up when experimenting was the cutting of the various samples, 
especially the catheter. The catheter was cut using a razor blade into rings of about 2 mm, but the 
accuracy of cutting with the blade was extremely difficult and caused irregular surfaces. To adjust for 
the differences in ring size, it was suggested to us by our advisor to weigh each sample in order to keep 
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them consistent for testing.  In terms of better cutting practices there are tools out there that could 
have helped. For instance, Thermoscientific™ and Scienceware® each have a polymer tubing cutter that 
is able to cut tubing with the help of guide holes of various sizes and costs about $43.18 and $25.20, 
respectively. Again, due to time constraints (takes about a month to ship); it was not feasible to 
purchase such a device. 
Future work  
 The future of this project begins with continued experimentation on incorporation. Absorbing 
Filastatin into medical materials can be affected by things the team did not have time to look into: 
swelling the material, using other solvents, Filastatin concentration. Swelling was identified as a 
possibility but ethanol was the only agent the team tested. Incorporation was done at 25uM 
concentration, but it is possible that the material would retain a therapeutic effect at lower 
concentrations. Determining the minimum concentration would lead to designing a more cost effective 
manufacturing process. In addition, full catheter can be put through the same testing to see a larger 
difference in cell adhesion compared to an uncoated catheter. Lastly, we saw effect of Filastatin 
absorbed for 2 days, but we need to test if it will work for longer time points. 
 The methods for incorporating Filastatin are simple, but without knowledge of the 
manufacturing process the team cannot be sure that scaling them up is feasible. Analyzing 
manufacturing facilities and the materials that they have access to would allow for optimization of the 
incorporation method for manufacturability. Other materials that are used for catheters could also be 
tested to avoid changes in manufacturing processes that have been optimized for different plastics.  
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Appendix A: 
Spider media (Sileika et al., 2011) 
Add the following substances into 1 liter ddH2O: 
Nutrient broth 13.5 grams 10 grams 
Mannitol 10 grams 
K2PO4  2 grams 
Autoclave the solution 
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Appendix B 
24-well cell adhesion assay on glass- C. albicans 
Day 1. 
Culture 
An overnight culture of freshly-struck wild-type C. albicans strain SC5314 is grown in 10 ml 
supplemented YNB broth (Yeast Nitrogen Broth + 2 % glucose + 0.1 mg/ml uridine), in a 30oC shaker. 
Material prep 
Squares of plastic are cut to 0.8 cm2 
Cleaning for APTMS treated materials (oxygen plasma) 
Clean squares briefly in 100% ethanol and dry using N2 
Place squares in the oxygen plasma unit and etch for 2 mins. 
In a petri dish, make a 1:10 dilution of APTMS to methanol solution and incubate for 12 hours.  
Wash the squares with methanol 2x and then with diH2O.  
Dry the squares using N2 and store at 4°C in a sterile glass petri dish sealed with parafilm. 
Cleaning for other incorporation methods 
Squares are cleaned with 100% ethanol and then placed individually on aluminum foil and sterilized by 
UV irradiation (four doses of 3000 µJ/cm2) 
Day 2 
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Incubation of squares 
Measure the OD of the overnight culture. 
Culture is spun down at 1000g for 5 mins and washed twice with spider media 
The culture is then diluted to 0.3 OD600/ml into fresh Spider media at 37 oC 
1.5 ml of diluted cells are added to each well of a 24-well plate and then squares followed by incubation 
in a humid 37oC chamber for 2.5 hrs.; rotating at 80 RPM. 
Aspirate media in each well and wash with 1 ml of PBS left on a rotator for 5 mins 
Analyzes using dyes 
Option 1: Crystal Violet 
Remove squares into another 24-well plate with 500 ul Crystal Violet incubate for 15 mins  
Wash squares 3x with ddH2O in same plate 
In a new 24-well plate, place squares in 350 ul 33% Acetic acid for 2 mins to remove the dye from the 
cells 
Take 100 ul of each condition in duplicate and measure absorbance at 590nm in a 96-well plate. 
Option 2: Alamar Blue 
Remove squares into another 24-well plate with 500 ul Alamar blue 
Fluorescence was measured directly on the cells after an hour of incubation  
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Appendix C 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 6 different replicates for the polymerization experiment 
 
 Thiolene network with 
Filastatin 
Thiolene network without 
Filastatin 
Control (Alamar + 
Water) 
 1918 2040 118 
 1820 1885 113 
 2040 1848 142 
 1925 1928 116 
 1958 1833 118 
 2114 2332 118 
Average 1962.5 1977.666667 120.8333333 
Std dev 102.6367381 188.8032486 10.55304064 
Std error 34.21224602 62.93441619 3.517680212 
Q1 1919.75 1857.25 116.5 
Q3 2019.5 2012 118 
IQR 99.75 154.75 1.5 
Upper 2169.125 2244.125 120.25 
Lower 1770.125 1625.125 114.25 
Normalize 1 1.007728238 0.061571125 
 
p-test comparisons 
Conditions p-test 
Thiolene network with Filastatin versus without Filastatin 0.867196 
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Appendix D 
Comparing Alamar blue accuracy to Crystal Violet 
An assay was conducted using the cell adhesion assay in Appendix B using silicone squares 
treated with APTMS and APTMS co-incubated with Filastatin (6 technical replicates). Both were analyzed 
using Alamar blue and Crystal Violet. The normalized mean fluorescence (Alamar blue) and absorbance 
(Crystal Violet) with standard error and percent of error per total normalized mean is shown below as 
well as the graphed results:  
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Alamar blue assay 
Condition Normalized average Standard error Standard  error percentage of total mean 
APTMS  1 0.1090 10.9% 
APTMS F 0.6523 0.0856 12.5% 
   
Crystal Violet Assay 
Condition Normalized average Standard error  Standard  error percentage of total mean 
APTMS  1 0.0247 2.47% 
APTMS F 0.6459 0.0387 5.99% 
 
As shown, the standard error percentage for Alamar blue is twice as much as Crystal violet. In addition, 
the Alamar blue assay takes one hour to incubate plus set-up time versus 15 minutes for crystal violet.  
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Appendix E 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 6 different replicates for the functionalizing agent experiment (3 readings per 
replicate) 
 
Uncoated 
Silicone 
Silicone + 
APTMS 
Silicone + APTMS + 
Filastatin 
Uncoated, coincubated in 
soluble Filastatin No cells 
 0.278 0.263 0.32 0.262 0.046 
 0.276 0.263 0.318 0.261 0.047 
 0.276 0.262 0.32 0.26 0.045 
 0.279 0.304 0.235 0.136 0.046 
 0.276 0.292 0.237 0.135 0.047 
 0.279 0.294 0.234 0.135 0.045 
 0.278 0.312 0.314 0.08 0.046 
 0.277 0.313 0.315 0.079 0.047 
 0.276 0.311 0.315 0.08 0.045 
Average 0.276666667 0.290444444 0.289777778 0.158666667 0.046 
Std dev 0.001 0.022108319 0.040895531 0.080448741 0.000866 
Std error 0.000333333 0.00736944 0.013631844 0.026816247 0.000289 
Q1 0.276 0.263 0.237 0.08 0.045 
Q3 0.278 0.311 0.318 0.26 0.047 
IQR 0.002 0.048 0.081 0.18 0.002 
Upper 0.281 0.383 0.4395 0.53 0.05 
Lower 0.273 0.191 0.1155 -0.19 0.042 
Normalize 1 1.049799197 1.047389558 0.573493976 0.166265 
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Appendix F 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 6 different replicates for the absorption experiment 
 Uncoated Filastatin absorbed Uncoated, coincubated in soluble Filastatin No cells 
 1.314 0.564 0.423 0.086 
 1.346 0.568 0.425 0.084 
 1.339 0.572 0.434 0.085 
 1.16 0.371 0.385 0.293 
 1.149 0.369 0.393 0.297 
 1.102 0.374 0.392 0.245 
 1.442 0.77 0.569 0.215 
 1.467 0.777 0.574 0.214 
 1.479 1 0.596 0.221 
Average 1.310889 0.596111 0.465667 0.193333 
Std dev 0.143381 0.217966 0.087387 0.086763 
Std error 0.047794 0.072655 0.029129 0.028921 
Q1 1.16 0.374 0.393 0.086 
Q3 1.442 0.77 0.569 0.245 
IQR 0.282 0.396 0.176 0.159 
Upper  1.865 1.364 0.833 0.4835 
Lower 0.737 -0.22 0.129 -0.1525 
Normalized 1 0.454738 0.35523 0.147483 
P-test comparisons 
 p-test 
Filastatin absorbed vs. Uncoated coincubated in soluble Filastatin 0.125118946 
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Appendix G 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 6 different replicates for the entrapment experiment 
 
 
 Uncoated 
Polydopamine 
coated 
Filastatin absorbed then 
Polydopamine coated 
Uncoated, coincubated in 
soluble Filastatin No cells 
 1.314 0.509 0.379 0.423 0.086 
 1.346 0.513 0.377 0.425 0.084 
 1.339 0.534 0.371 0.434 0.085 
 1.16 0.615 0.284 0.385 0.293 
 1.149 0.596 0.286 0.393 0.297 
 1.102 0.603 0.289 0.392 0.245 
 1.442 0.807 0.28 0.569 0.215 
 1.467 0.799 0.276 0.574 0.214 
 1.479 0.833 0.278 0.596 0.221 
Average 1.310889 0.645444 0.313333 0.465667 0.193333 
Std dev 0.143381 0.131628 0.046963 0.087387 0.086763 
Std error 0.047794 0.043876 0.015654 0.029129 0.028921 
Q1 1.16 0.534 0.28 0.393 0.086 
Q3 1.442 0.799 0.371 0.569 0.245 
IQR 0.282 0.265 0.091 0.176 0.159 
Upper  1.865 1.1965 0.5075 0.833 0.4835 
Lower 0.737 0.1365 0.1435 0.129 -0.1525 
Normalized 1 0.492372 0.239024 0.35523 0.147483 
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P-test comparisons 
 p-test 
Polydopamine vs. Uncoated coincubated in soluble Filastatin 0.004234438 
Polydopamine vs. Filastatin then Polydopamine 3.17582E-05 
Filastatin then Polydopamine vs. Uncoated coincubated in soluble Filastatin 0.000570982 
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Appendix H: 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 3 biological replicates for the absorption and entrapment experiments of silicone 
squares. 
Replicate 1: (3 squares, 3 readings each) 
01_14_16 
Uncoate
d 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed then 
Polydopamine coated 
Uncoated, coincubated 
in soluble Filastatin No cells 
 1.314 0.509 0.564 0.379 0.423 0.086 
 1.346 0.513 0.568 0.377 0.425 0.084 
 1.339 0.534 0.572 0.371 0.434 0.085 
 1.16 0.615 0.371 0.284 0.385 0.293 
 1.149 0.596 0.369 0.286 0.393 0.297 
 1.102 0.603 0.374 0.289 0.392 0.245 
 1.442 0.807 0.77 0.28 0.569 0.215 
 1.467 0.799 0.777 0.276 0.574 0.214 
 1.479 0.833 1 0.278 0.596 0.221 
Average 1.310889 0.596111 0.645444 0.313333 0.465667 
0.19333
3 
Std dev 0.143381 0.217966 0.131628 0.046963 0.087387 
0.08676
3 
Std error 0.047794 0.072655 0.043876 0.015654 0.029129 
0.02892
1 
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Q1 1.16 0.534 0.374 0.28 0.393 0.086 
Q3 1.442 0.799 0.77 0.371 0.569 0.245 
IQR 0.282 0.265 0.396 0.091 0.176 0.159 
Upper 1.865 1.1965 1.364 0.5075 0.833 0.4835 
Lower 0.737 0.1365 -0.22 0.1435 0.129 -0.1525 
Normalize
d 1 0.454738 0.492372 0.239024 0.35523 
0.14748
3 
 
Replicate 2: (6 squares, 2 readings each) 
02_10_16 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed 
then Polydopamine 
coated 
Uncoated, 
coincubated in 
soluble Filastatin No cells 
 0.989 0.453 0.706 0.724 0.557 0.116 
 0.991 0.449 0.712 0.729 0.564 0.118 
 1.061 0.441 0.58 0.561 0.475 0.148 
 0.632 0.445 0.581 0.559 0.478 0.144 
 0.669 0.286 0.575 0.489 0.622 0.123 
 0.631 0.284 0.572 0.488 0.614 0.121 
 0.897 0.517 0.558 0.396 0.3 0.121 
 0.889 0.519 0.572 0.404 0.297 0.12 
 0.889 0.588 0.515 0.565 0.18 0.14 
 0.945 0.59 0.515 0.644 0.193 0.14 
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 0.934 0.602 0.303 0.599 0.495 0.103 
 0.794 0.601 0.312 0.594 0.493 0.104 
Average 0.860083 0.48125 0.5585 0.562667 0.439 0.124833 
Std dev 0.14623 0.111457 0.027749 0.107276 0.156558 0.014941 
Std error 0.024372 0.018576 0.006937 0.017879 0.026093 0.00249 
Q1 0.76275 0.444 0.515 0.48875 0.29925 0.1175 
Q3 0.956 0.5885 0.58025 0.61025 0.55875 0.14 
IQR 0.19325 0.1445 0.06525 0.1215 0.2595 0.0225 
Upper 1.245875 0.80525 0.678125 0.7925 0.948 0.17375 
Lower 0.472875 0.22725 0.417125 0.3065 -0.09 0.08375 
Normalized 1 0.559539 0.649356 0.6542 0.510416 0.145141 
 
Yellow = Outlier that was not included 
Replicate 3: (6 squares, 2 readings each) 
02_14_16 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed 
then Polydopamine 
coated 
Uncoated, 
coincubated in 
soluble Filastatin No cells 
 0.983 0.685 0.708 0.305 0.356 0.144 
 0.99 0.694 0.715 0.303 0.36 0.145 
 0.796 1.018 0.657 1.089 0.134 0.098 
 0.798 1.022 0.66 1.078 0.14 0.097 
 0.83 0.681 0.699 1.415 0.083 0.146 
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 0.828 0.684 0.71 1.416 0.082 0.145 
 0.377 1.121 0.521 0.514 0.142 0.195 
 0.377 1.116 0.523 0.517 0.144 0.196 
 0.714 0.59 0.869 0.824 0.418 0.131 
 0.713 0.586 0.868 0.824 0.42 0.131 
 0.741 0.675 0.81 1.073 0.428 0.103 
 0.747 0.671 0.808 1.071 0.428 0.102 
Average 0.814 0.79525 0.712333 0.869083 0.26125 0.136083 
Std dev 0.100326 0.207512 0.115181 0.388968 0.149811 0.033934 
Std error 0.020065 0.034585 0.019197 0.064828 0.024969 0.005656 
Q1 0.71375 0.674 0.65925 0.51625 0.1385 0.10275 
Q3 0.8285 1.019 0.8085 1.08075 0.4185 0.14525 
IQR 0.11475 0.345 0.14925 0.5645 0.28 0.0425 
Upper 
Fence 1.000625 1.5365 1.032375 1.9275 0.8385 0.209 
Lower 
Fence 0.541625 0.1565 0.435375 -0.3305 -0.2815 0.039 
Normalized 1 0.976966 0.875102 1.06767 0.320946 0.167179 
Yellow = Outlier that was not include 
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Averaged Values: 
Combined Average 1 0.663747 0.672277 0.653631 0.39553 0.153267 
Std dev 0 0.27627 0.192392 0.414323 0.100959 0.012104 
Std error 0 0.09209 0.064131 0.138108 0.033653 0.004035 
 
ANOVA: Single Factor comparisons 
 P-value 
Polydopamine coated vs. Filastatin absorbed vs. Filastatin absorbed then 
Polydopamine coated vs. Uncoated coincubated in soluble Filastatin 0.8411 
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Appendix I: 
Serial dilution readings 
 
 
 
Concentration (uM) Reading 1 Reading 2 Average Std deviation 
1.56 0.011 0.023 0.017 0.008485281 
3.125 0.024 0.031 0.0275 0.004949747 
6.25 0.06 0.055 0.0575 0.003535534 
12.5 0.129 0.127 0.128 0.001414214 
25 0.251 0.213 0.232 0.026870058 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
Appendix J: 
Absorbance readings, mean and Standard Deviation of Silicone squares 
Absorption 
testing Absorbance at 400 nm   
Time (mins) 1 2 3 4 5 6 Average SD 
0 0.34 0.396 0.401 0.376 0.367 0.354 0.372333 0.023687 
10 0.277 0.335 0.354 0.331 0.317 0.295 0.318167 0.02816 
30 0.232 0.287 0.315 0.292 0.269 0.253 0.274667 0.029669 
60 0.201 0.251 0.286 0.261 0.239 0.223 0.2435 0.029717 
120 0.168 0.213 0.242 0.224 0.201 0.173 0.2035 0.028947 
240 0.132 0.16 0.183 0.178 0.157 0.092 0.150333 0.033792 
480 0.029 0.038 0.053 0.051 0.033 0.053 0.042833 0.010815 
1440 0.027 0.039 0.044 0.046 0.042 0.038 0.039333 0.006743 
2880 0.032 0.033 0.034 0.035 0.031 0.032 0.032833 0.001472 
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Appendix K: 
Elution readings, mean and Standard Deviation of absorption and entrapment silicone squares  
Filastatin absorbed: 
 1 2 3 Average Standard dev 
0 0.002 0.003 0.002 0.002333 0.000577 
10 0.003 0.018 0.004 0.008333 0.008386 
30 0.006 0.019 0.005 0.01 0.00781 
60 0.009 0.022     0.010 0.0155 0.009192 
120 0.018 0.015     0.013 0.0165 0.002121 
300 0.016 0.03 0.016 0.020667 0.008083 
2520 0.029 0.031 0.024 0.028 0.003606 
Filastatin absorbed then polydopamine coated: 
 1 2 3 Average Standard dev 
0 0.005 0.003 0.011 0.006333 0.004163 
10 0.008     0.008 0.014 0.011 0.004243 
30 0.009 0.014 0.015 0.012667 0.003215 
60 0.013 0.018 0.018 0.016333 0.002887 
120 0.021 0.029 0.025 0.025 0.004 
300 0.026     0.030 0.027 0.0265 0.000707 
2520 0.028 0.034 0.029 0.030333 0.003215 
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Appendix L: 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization for the absorption and entrapment experiments of Pellethane squares. 
 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed then 
Polydopamine coated 
Uncoated 
coincubated in 
soluble Filastatin No cells 
 2728 3638 3181 3933 1469 255 
 2762 3658 3300 4042 1455 250 
 3083 3702 3245 2907 2299 256 
 3052 3862 3266 2960 2274 265 
 2687 3330 2509 3473 2003 264 
 2464 3420 2622 3598 1987 268 
 3091 2890 2726 1855 2274 264 
 3067 2832 2769 1918 2346 268 
 3051 2453 2489 2303 2499 260 
 2787 2509 2593 2348 2558 265 
 2756 3535 2864 2597 2191 258 
 2788 3403 2816 2630 2164 250 
Average 2859.667 3269.333 2865 2880.333 2126.583 260.25 
Std dev 203.243 478.6267 305.4603 742.7201 352.8964 6.426154 
Std error 67.74765 159.5422 101.8201 247.5734 117.6321 2.142051 
Q1 2749 2875.5 2614.75 2336.75 1999 255.75 
Q3 3055.75 3643 3197 3504.25 2310.75 265 
IQR 306.75 767.5 582.25 1167.5 311.75 9.25 
Upper 3515.875 4794.25 4070.375 5255.5 2778.375 278.875 
Lower 2288.875 1724.25 1741.375 585.5 1531.375 241.875 
Normalized 1 1.143257 1.001865 1.007227 0.743647 0.091007 
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Appendix M: 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization for the absorption and entrapment experiments of polyurethane squares. 
 Uncoated 
Filastatin 
absorbed 
Polydopamine 
coated 
Filastatin absorbed then 
Polydopamine coated 
Uncoated 
coincubated in 
soluble Filastatin No cells 
 0.519 0.583 0.222 0.257 0.24 0.119 
 0.523 0.582 0.227 0.26 0.238 0.119 
 0.556 0.391 0.347 0.331 0.317 0.119 
 0.558 0.387 0.342 0.331 0.319 0.119 
 0.313 0.407 0.312 0.448 0.346 0.119 
 0.309 0.404 0.335 0.443 0.342 0.119 
 0.292 0.508 0.577 0.323 0.339 0.119 
 0.289 0.509 0.563 0.332 0.342 0.119 
 0.545 0.465 0.378 0.764 0.194 0.16 
 0.549 0.466 0.371 0.749 0.195 0.159 
 0.604 0.238 0.404 0.829 0.264 0.145 
 0.621 0.239 0.408 0.812 0.263 0.142 
Average 0.473167 0.431583 0.373833 0.340625 0.28325 0.129833 
Std dev 0.130686 0.112512 0.109063 0.071787 0.057854 0.016727 
Std error 0.021781 0.018752 0.018177 0.011965 0.009642 0.002788 
Q1 0.312 0.39 0.32925 0.329 0.2395 0.119 
Q3 0.5565 0.50825 0.405 0.75275 0.33975 0.14275 
IQR 0.2445 0.11825 0.07575 0.42375 0.10025 0.02375 
Upper 0.92325 0.685625 0.518625 1.388375 0.490125 0.178375 
Lower -0.05475 0.212625 0.215625 -0.30663 0.089125 0.083375 
Normalized 1 0.912117 0.790067 0.719884 0.598626 0.274392 
Yellow = Outlier that was not include  
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Appendix N: 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization for the absorption and entrapment experiments of two cuts of silicone catheter. 
Rings Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed then 
Polydopamine coated 
Uncoated coincubated 
in soluble Filastatin 
No cells 
 1.05 0.32 0.262 0.689 0.598 0.125 
 1.067 0.322 0.263 0.697 0.606 0.124 
 1.349 0.325 0.355 0.849 0.419 0.122 
 1.359 0.335 0.355 0.851 0.412 0.121 
 0.69 0.328 0.626 0.689 0.555 0.106 
 0.678 0.333 0.615 0.686 0.555 0.104 
Average 
1.032167 0.327167 0.30875 0.7435 0.524167 0.117 
Std dev 
0.300415 0.005981 0.053406 0.082578 0.086823 0.009423 
Std error 
0.100138 0.001994 0.026703 0.027526 0.028941 0.003141 
Q1 0.78 0.26825 0.286 0.689 0.453 0.10975 
Q3 1.2785 0.3265 0.55 0.811 0.58725 0.1235 
IQR 0.4985 0.05825 0.264 0.122 0.13425 0.01375 
Upper 2.02625 0.413875 0.946 0.994 0.788625 0.144125 
Lower 0.03225 0.180875 -0.11 0.506 0.251625 0.089125 
Normalized  1 0.291297 0.299128 0.720329 0.507831 0.113354 
 
Yellow = Outlier that was not include 
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Curves Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed 
then Polydopamine 
coated 
Uncoated 
coincubated 
in soluble 
Filastatin No cells 
 0.611 0.583 0.446 0.704 0.653 0.109 
 0.611 0.581 0.442 0.71 0.652 0.109 
 0.82 0.291 0.655 0.614 0.43 0.065 
 0.824 0.292 0.657 0.618 0.43 0.065 
 0.739 0.274 0.708 0.782 0.574 0.089 
 0.733 0.27 0.708 0.781 0.572 0.088 
Average 0.723 0.381833 0.602667 0.7015 0.551833 0.0875 
Std dev 0.094925 0.125091 0.1553 0.074172 0.100849 0.019695 
Std error 0.031642 0.041697 0.051767 0.024724 0.033616 0.006565 
Q1 0.6415 0.27825 0.49825 0.6395 0.4655 0.07075 
Q3 0.79975 0.50875 0.69525 0.76325 0.6325 0.104 
IQR 0.15825 0.2305 0.197 0.12375 0.167 0.03325 
Upper 1.037125 0.8545 0.99075 0.948875 0.883 0.153875 
Lower 0.404125 -0.0675 0.20275 0.453875 0.215 0.020875 
Normalized 1 0.528124 0.833564 0.970263 0.763255 0.121024 
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Appendix O: 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 3 biological for the absorption and entrapment experiments of silicone catheter 
pieces. 
Replicate 1: (3 pieces, 2 readings each) 
2_17_16 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed then 
Polydopamine coated 
Uncoated 
coincubated in 
soluble Filastatin 
No cells 
 1.05 0.32 0.262 0.689 0.598 0.125 
 1.067 0.322 0.263 0.697 0.606 0.124 
 1.349 0.325 0.355 0.849 0.419 0.122 
 1.359 0.335 0.355 0.851 0.412 0.121 
 0.69 0.328 0.626 0.689 0.555 0.106 
 0.678 0.333 0.615 0.686 0.555 0.104 
Average 
1.032167 0.327167 0.30875 0.7435 0.524167 0.117 
Std dev 
0.300415 0.005981 0.053406 0.082578 0.086823 0.009423 
Std error 
0.100138 0.001994 0.026703 0.027526 0.028941 0.003141 
Q1 0.78 0.26825 0.286 0.689 0.453 0.10975 
Q3 1.2785 0.3265 0.55 0.811 0.58725 0.1235 
IQR 0.4985 0.05825 0.264 0.122 0.13425 0.01375 
Upper 2.02625 0.413875 0.946 0.994 0.788625 0.144125 
Lower 0.03225 0.180875 -0.11 0.506 0.251625 0.089125 
Normalized  1 0.291297 0.299128 0.720329 0.507831 0.113354 
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Yellow = Outlier that was not include 
Replicate 2: (6 pieces, 2 readings each) 
2_24_16 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin absorbed then 
Polydopamine coated No cells 
 0.801 0.242 0.419 0.264 0.123 
 0.801 0.241 0.419 0.264 0.123 
 0.978 0.346 0.386 0.203 0.138 
 0.985 0.343 0.385 0.202 0.138 
 1.02 0.397 0.443 0.257 0.17 
 1.016 0.398 0.446 0.261 0.17 
 0.72 0.393 0.662 0.374 0.182 
 0.717 0.394 0.663 0.376 0.182 
 0.995 0.55 0.379 0.282 0.19 
 0.99 0.565 0.383 0.286 0.19 
 0.63 0.436 0.337 0.307 0.162 
 0.635 0.436 0.343 0.308 0.161 
Average 0.857333 0.395083 0.394 0.282 0.16075 
Q1 0.76275 0.444 0.515 0.48875 0.29925 
Q3 0.956 0.5885 0.58025 0.61025 0.55875 
IQR 0.19325 0.1445 0.06525 0.1215 0.2595 
Upper 
Fence 1.245875 0.80525 0.678125 0.7925 0.948 
Lower 
Fence 0.472875 0.22725 0.417125 0.3065 -0.09 
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Normalized 1.044618 0.643052 0.634038 0.610545 0 
Yellow = Outlier that was not include 
Replicate 3: (6 pieces, 2 readings each) 
3_2_16 
Uncoated 
Filastatin 
absorbed 
Filastatin absorbed then 
Polydopamine coated 
Uncoated coincubated in 
soluble Filastatin No cells 
 0.749 0.451 0.409 0.321 0.106 
 0.747 0.461 0.409 0.322 0.107 
 0.984 0.561 0.478 0.461 0.109 
 0.98 0.557 0.472 0.463 0.108 
 0.707 0.459 0.543 0.42 0.106 
 0.709 0.462 0.557 0.483 0.106 
 0.753 0.502 0.561 0.454 0.087 
 0.748 0.503 0.568 0.47 0.086 
 1.41 0.572 0.482 0.482 0.091 
 1.413 0.57 0.482 0.493 0.092 
 1.579 0.442 0.442 0.437 0.097 
 1.578 0.439 0.436 0.44 0.098 
Average 1.02975 0.49825 0.486583 0.4603 0.099417 
Q1 0.71375 0.674 0.65925 0.51625 0.1385 
Q3 0.8285 1.019 0.8085 1.08075 0.4185 
IQR 0.11475 0.345 0.14925 0.5645 0.28 
Upper 
Fence 1.000625 1.5365 1.032375 1.9275 0.8385 
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Lower 
Fence 0.541625 0.1565 0.435375 -0.3305 -0.2815 
Normalized 1 0.428699 0.416159 0.387908 0 
Yellow = Outlier that was not include 
ANOVA: Single Factor comparisons 
 P-value 
Polydopamine coated vs. Filastatin absorbed vs. Filastatin absorbed then 
Polydopamine coated vs. Uncoated coincubated in soluble Filastatin 0.642693 
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Appendix P: 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 2 biological replicates for the absorption and entrapment experiments of silicone 
catheter pieces at 22 hr. incubation (1000 cells/ml). 
Replicate 1: (6 pieces, 2 readings each) 
3_12_16 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin 
absorbed 
then 
Polydopamine 
coated 
Uncoated 
coincubated 
in soluble 
Filastatin 
No cells 
 0.481 1.043 0.167 0.741 0.319 0.11 
 0.474 1.037 0.17 0.746 0.33 0.11 
 0.499 0.772 0.277 0.533 0.245 0.115 
 0.504 0.786 0.27 0.532 0.247 0.116 
 0.38 1.387 0.188 0.39 0.313 0.115 
 0.378 1.375 0.186 0.384 0.312 0.116 
 0.307 0.53 0.251 0.525 0.283 0.112 
 0.31 0.592 0.257 0.523 0.285 0.112 
 0.571 1.042 0.189 0.673 0.23 0.079 
 0.571 1.037 0.189 0.677 0.227 0.079 
 0.387 0.966 0.389 0.602 0.245 0.11 
 0.387 0.977 0.389 0.612 0.241 0.116 
Average 0.437417 0.962 0.2144 0.578167 0.273083 0.112625 
Std dev 0.091605 0.263929 0.043686 0.119964 0.038094 0.002669 
Std error 0.015268 0.043988 0.007281 0.019994 0.006349 0.000445 
Q1 0.3795 0.7825 0.1875 0.5245 0.244 0.11 
Q3 0.50025 1.04225 0.27175 0.674 0.31225 0.116 
IQR 0.12075 0.25975 0.08425 0.1495 0.06825 0.006 
Upper 0.681375 1.431875 0.398125 0.89825 0.414625 0.125 
Lower 0.198375 0.392875 0.061125 0.30025 0.141625 0.101 
Normalized 1 0.490151 2.199276 1.321776 0.624309 0.257478 
Yellow = Outlier that was not include 
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Replicate 2: (6 pieces, 2 readings each) 
4_11_16 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin 
absorbed 
then 
Polydopamine 
coated 
Uncoated 
coincubated 
in soluble 
Filastatin 
No cells 
 0.308 0.648 0.148 0.568 0.275 0.12 
 0.316 0.641 0.151 0.562 0.273 0.119 
 0.372 0.53 0.197 0.693 0.254 0.149 
 0.372 0.529 0.18 0.693 0.256 0.15 
 0.226 0.468 0.155 0.83 0.24 0.111 
 0.233 0.459 0.156 0.824 0.239 0.111 
 0.361 0.797 0.143 0.841 0.183 0.131 
 0.363 0.788 0.144 0.838 0.185 0.131 
 0.288 0.867 0.155 0.74 0.181 0.117 
 0.288 0.859 0.157 0.749 0.18 0.117 
 0.319 0.453 0.163 0.694 0.213 0.148 
 0.317 0.46 0.165 0.687 0.229 0.15 
Average 0.313583 0.6586 0.156091 0.726583 0.225667 0.13725 
Std dev 0.049605 0.159657 0.01054 0.096997 0.036315 0.013562 
Std error 0.008267 0.02661 0.001757 0.016166 0.006053 0.00226 
Q1 0.288 0.466 0.15025 0.6915 0.1845 0.117 
Q3 0.3615 0.79025 0.1635 0.8255 0.2545 0.14825 
IQR 0.0735 0.32425 0.01325 0.134 0.07 0.03125 
Upper 
Fence 0.47175 1.276625 0.183375 1.0265 0.3595 0.195125 
LowerFence 0.17775 -0.02038 0.130375 0.4905 0.0795 0.070125 
Normalized 1 1.992825 0.490141 2.317034 0.719639 0.412968 
Yellow = Outlier that was not include 
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Appendix Q: 
Plate readings, mean, Standard Deviation, Standard Error, Upper and Lower outlier identification, and 
Normalization from 2 biological replicates for the absorption and entrapment experiments of silicone 
catheter pieces at 45 hr. incubation (1000 cells/ml). 
4_12_16 Uncoated 
Polydopamine 
coated 
Filastatin 
absorbed 
Filastatin then 
Polydopamine 
coated 
Uncoated, 
coincubated 
with soluble 
Filastatin No cells 
 0.479 0.842 0.117 0.498 0.331 0.104 
 0.491 0.847 0.12 0.489 0.33 0.111 
 0.929 0.932 0.137 0.627 0.229 0.104 
 0.953 0.937 0.126 0.648 0.236 0.106 
 0.791 0.546 0.187 0.777 0.58 0.109 
 0.842 0.559 0.192 0.783 0.618 0.11 
 0.545 1.498 0.176 1.353 0.364 0.09 
 0.549 1.611 0.179 1.405 0.378 0.089 
 1.309 0.68 0.164 0.706 0.304 0.175 
 1.342 0.694 0.165 0.699 0.321 0.175 
 0.529 0.744 0.093 0.663 0.313 0.15 
 0.552 0.77 0.094 0.668 0.321 0.149 
Average 0.775917 0.7551 0.145833 0.6558 0.3127 0.122667 
Std dev 0.30885 0.336253 0.035652 0.295745 0.04788 0.031008 
Std error 0.051475 0.056042 0.005942 0.049291 0.00798 0.005168 
Q1 0.541 0.6905 0.11925 0.64275 0.31075 0.104 
Q3 0.935 0.93325 0.17675 0.7785 0.3675 0.14925 
IQR 0.394 0.24275 0.0575 0.13575 0.05675 0.04525 
Upper 
Fence 1.526 1.297375 0.263 0.982125 0.452625 0.217125 
LowerFence -0.05 0.326375 0.033 0.439125 0.225625 0.036125 
Normalized 1 0.973172 0.18795 0.845194 0.403007 0.158093 
Yellow = Outlier that was not include 
P-test comparison 
 P-value 
Filastatin absorbed vs. No cells 0.1035 
 
